

78688

Access DB#

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: PATEL SUDHAKER Examiner #: 77018 Date: 10/25/02
Art Unit: 1624 Phone Number 301 84789 Serial Number: 10087715
Mail Box and Bldg/Room Location: CM1 4E12 Results Format Preferred (circle) PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.




Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

COMPOUNDS USEFUL FOR INHIBITING CHK1
Title of Invention:

Inventors (please provide full names): KATHLEEN S. KEEGAN et al.

Earliest Priority Filing Date: 3/2/2001

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued parent numbers) along with the appropriate serial number.



Need info @ gels, composition & use as inhibitors of CHECKPOINT KINASE 1 in a cell. Copy claims enclosed. Need: d flab hetero also told in CAPUS for THX.

STAFF USE ONLY

Point of Contact:
Searcher: Alexandra Wacław
Technical Info: Specialist
CM1 8A02 Tel: 308-4491
Searcher Location:
Date Searcher Picked Up: 11-7
Date Completed: 11-7
Searcher Prep & Review Time: 25
Clerical Prep Time:
Online Time: 72

Type of Search

NA Sequence (#)
AA Sequence (#)
Structure (#) 3
Bibliographic
Litigation
Fulltext
Patent Family
Other

Vendors and cost where applicable

STN \$505
Dialog
Questel/Orbit
Dr. Link
Lexis/Nexis
Sequence Systems
WWW/Internet
Other (specify)

RECEIVED
OCT 25 2002
P-15
435
37

⇒ d his

(FILE 'HCAPLUS' ENTERED AT 12:10:06 ON 07 NOV 2002)
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 12:10:49 ON 07 NOV 2002
ACT PATEL087/A

L1 STR
L2 564 SEA FILE=REGISTRY SSS FUL L1

ACT PATEL087C/A

L3 STR
L4 (564) SEA FILE=REGISTRY SSS FUL L3
L5 STR
L6 STR
L7 STR
L8 95 SEA FILE=REGISTRY SUB=L4 SSS FUL L5 OR L6 OR L7

L9 469 S L2 NOT L8

FILE 'HCAPLUS' ENTERED AT 12:11:07 ON 07 NOV 2002
L10 1 S L8
L11 122 S L9
L12 242 S CHK1 OR CHK1/AB
L13 83 S CHECKPOINT KINASE?
L14 288 S L12 OR L13
L15 1 S L11 AND L14
L16 415003 S NEOPLAS? OR CANCER? OR CARCINOMA? OR TUMOR#
L17 4 S L11 AND L16
L18 4 S L15 OR L17

=> fil-reg

FILE 'REGISTRY' ENTERED AT 12:17:44 ON 07 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 6 NOV 2002 HIGHEST RN 471238-76-3
DICTIONARY FILE UPDATES: 6 NOV 2002 HIGHEST RN 471238-76-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d his 11-19

(FILE 'HCAPLUS' ENTERED AT 12:10:06 ON 07 NOV 2002)
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 12:10:49 ON 07 NOV 2002
ACT PATEL087/A

L1 STR
L2 564 SEA FILE=REGISTRY SSS FUL L1

ACT PATEL087C/A

L3 STR
L4 (564) SEA FILE=REGISTRY SSS FUL L3
L5 STR
L6 STR
L7 STR

L8 95 SEA FILE=REGISTRY SUB=L4 SSS FUL L5 OR L6 OR L7


L9 469 S L2 NOT L8

=> d que stat12
'STATL2' IS NOT VALID HERE

=> d que-stat-12
L1 STR

- Claim 3. (claims 1 and 2
were too broad to search)

Claim 28



VAR G1=3/9/15/21/27/33/44
 VAR G2=O/S
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 GGCAT IS MCY UNS AT 51
 DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:
 RSPEC I
 NUMBER OF NODES IS 52

STEREO ATTRIBUTES: NONE
 L2 564 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 6622 ITERATIONS
 SEARCH TIME: 00.00.05

564 ANSWERS

=> d que stat 18;d his 19
 L3 STR



VAR G1=3/9/15/21/27/33/44
 VAR G2=O/S

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 51
DEFAULT ECLEVEL IS LIMITED



GRAPH ATTRIBUTES:

RSPEC I
NUMBER OF NODES IS 52

STEREO ATTRIBUTES: NONE

L4 (564)SEA FILE=REGISTRY SSS FUL L3
L5 STR

CH2-CH2Hy
@38 39 40



VAR G1=38/41

NODE ATTRIBUTES:


DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 40
GGCAT IS MCY UNS AT 52
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E5 C E1 N AT 40

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE



L6 STR




NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE
 L7 STR




NH~Cb
 @30 31



Me~N~Cb
 32 @33 34

Me~N~Me
 35 @36 37

CH2~CH2~Hy
 @38 39 40



VAR G2=20/26
 VAR G3=30/33/36
 VAR G4=38/41
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 GGCAT IS MCY SAT AT 31

Patel 10/087,715

GGCAT IS MCY SAT AT 34
GGCAT IS MCY UNS AT 40
GGCAT IS MCY UNS AT 47
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E5 C AT 31
ECOUNT IS E6 C AT 34
ECOUNT IS E5 C E1 N AT 40

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 47

STEREO ATTRIBUTES: NONE

L8 95 SEA FILE=REGISTRY SUB=L4 SSS-FUL L5 OR L6 OR L7

100.0% PROCESSED 175 ITERATIONS
SEARCH TIME: 00.00.04

95 ANSWERS

1, 2, 3 cover claim 28

(FILE 'REGISTRY' ENTERED AT 12:10:49 ON 07 NOV 2002)

L9 469 S L2 NOT L8

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 12:18:14 ON 07 NOV 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Nov 2002 VOL 137 ISS 19

FILE LAST UPDATED: 6 Nov 2002 (20021106/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d his l10-

(FILE 'HCAPLUS' ENTERED AT 12:11:07 ON 07 NOV 2002)

L10 1 S L8

L11 122 S L9

L12 242 S CHK1 OR CHK1/AB
 L13 83 S CHECKPOINT KINASE?
 L14 288 S L12 OR L13
 L15 1 S L11 AND L14
 L16 415003 S NEOPLAS? OR CANCER? OR CARCINOMA? OR TUMOR#
 L17 4 S L11 AND L16
~~L18 4 S L15 OR L17~~

FILE 'REGISTRY' ENTERED AT 12:17:44 ON 07 NOV 2002

FILE 'HCAPLUS' ENTERED AT 12:18:14 ON 07 NOV 2002

=> d .ca hitstr l10 1;d .ca hitstr l18 104

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:695962 HCAPLUS
 DOCUMENT NUMBER: 137:232680
 TITLE: Preparation of aryl and heteroaryl urea selective Chk1
 inhibitors for use as radiosensitizers and
 chemosensitizers for treating diseases and conditions
 related to DNA damage or lesions in DNA replication
 INVENTOR(S): Keegan, Kathleen S.; Kesicki, Edward A.; Gaudino, John
 Joseph; Cook, Adam Wade; Cowen, Scott Douglas;
 Burgess, Laurence Edward
 PATENT ASSIGNEE(S): Icos Corporation, USA
 SOURCE: PCT Int. Appl., 236 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002070494	A1	20020912	WO 2002-US6452	20020301
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-273124P P 20010302

OTHER SOURCE(S): MARPAT 137:232680

AB Aryl- and heteroaryl substituted urea compds. (W'NHC(:Y')N(R13)Z'; 1)
 useful in the treatment of diseases and conditions related to DNA damage
 or lesions in DNA replication are disclosed. In 1, W' is a six-membered
 arom. ring contg. at least 2 nitrogen atoms (e.g. pyrazinyl, pyrimidinyl,
 pyridazinyl, 1,2,4-triazinyl, quinoxalinyl) and optionally substituted as
 defined in the claims, Z' is a five- or six membered arom. or heteroarom.
 ring as defined in the claims, Y' is O or S. The first claim contains a
 much more general formula WX1C(:Y)X2Z (e.g. X1 = null, O, S, CH2, NR1; X2
 = O, S, NR1) but emphasis is on 1. Methods of making the compds., and
 their use as therapeutic agents, for example, in treating cancer and other
 diseases characterized by defects in DNA replication, chromosome
 segregation, or cell division also are described. Although the methods of
 prepn. are not claimed, about 200 example prepn. are included.
 N-(2-methoxy-5-methylphenyl)-N'-(2-pyrazinyl)urea and N-(4-chloro-2-

methoxyphenyl)-N'-(2-pyrazinyl)urea enhanced the killing of various human cells by 5-fluorouracil from 2- to 10-fold; in HeLa cells, these same compds. enhanced killing by irradiation 2-3 fold.

- IC ICM C07D241-20
ICS C07D401-12; C07D403-12; C07D241-54; A61K031-4965; A61K031-498; A61P035-00; C07D405-12; C07D251-22; C07D231-40; C07D239-46; C07D253-06; C07D239-42; C07D257-06; C07D213-75; C07D277-48
- CC 28-19 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
- IT 457096-68-3P, 1-(2-Methoxy-5-nitrophenyl)-3-(pyrazin-2-yl)urea
457096-69-4P, 1-(5-Amino-2-methoxyphenyl)-3-(pyrazin-2-yl)urea
457096-71-8P, (S)-1-(2,2,2-Trifluoroethanoyl)pyrrolidine-2-carboxylic acid
[4-methoxy-3-(3-(pyrazin-2-yl)ureido)phenyl]amide 457096-74-1P,
1-(2-Methoxy-4-nitrophenyl)-3-(pyrazin-2-yl)urea 457096-75-2P,
1-(4-Amino-2-methoxyphenyl)-3-(pyrazin-2-yl)urea 457096-78-5P,
3-Chloro-N-[3-methoxy-4-(3-(pyrazin-2-yl)ureido)phenyl]propionamide
457097-32-4P, 4-Methoxy-3-(3-(pyrazin-2-yl)ureido)benzoic acid
457097-53-9P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzoic acid
457099-26-2P, 1-(6-Azidopyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-29-5P, 1-(5-Bromopyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-31-9P, 1-[5-(1,3-Dioxo-1,3-dihydroisoindol-2-ylmethyl)pyrazin-2-yl]-3-(2-methoxy-5-methylphenyl)urea 457099-45-5P, 1-(5-Benzoylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-67-1P, 1-(4-Aminomethyl-2-methoxyphenyl)-3-(5-methylpyrazin-2-yl)urea
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; prepn. of aryl and heteroaryl urea selective Chk1 inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT 196868-94-7P, N-(4-Chloro-2-methoxyphenyl)-N'-(2-pyrazinyl)urea
457096-65-0P, 1-[2-(1,1-Difluoromethoxy)phenyl]-3-(pyrazin-2-yl)urea
457096-67-2P, 1-(2-Methylsulfanyphenyl)-3-(pyrazin-2-yl)urea
457096-70-7P, N-[4-Methoxy-3-(3-(pyrazin-2-yl)ureido)phenyl]succinamic acid 457096-72-9P, (S)-Pyrrolidine-2-carboxylic acid
[4-methoxy-3-(3-(pyrazin-2-yl)ureido)phenyl]amide 457096-73-0P,
N-[4-Methoxy-3-(3-(pyrazin-2-yl)ureido)phenyl]methanesulfonamide
457096-77-4P, C-Dimethylamino-N-[3-methoxy-4-(3-(pyrazin-2-yl)ureido)phenyl]acetamide trifluoroacetate 457096-79-6P,
N-(4-((3-(Cyclohexyl(methyl)amino)propanoyl)amino)-2-methoxyphenyl)-N'-(2-pyrazinyl)urea 457096-80-9P, 3-(Cyclohexyl(methyl)amino)-N-[3-methoxy-4-(3-(pyrazin-2-yl)ureido)phenyl]propionamide trifluoroacetate 457096-81-0P, 3-(Cyclopentylamino)-N-[3-methoxy-4-(3-(pyrazin-2-yl)ureido)phenyl]propionamide 457096-82-1P, 3-Methoxy-4-(3-(pyrazin-2-yl)ureido)benzoic acid 457096-85-4P, N-Butyl-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide 457096-86-5P, 1-[4-[(Benzylmethylamino)methyl]-2-methoxyphenyl]-3-(5-methylpyrazin-2-yl)urea 457096-87-6P,
N-Benzyl-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide 457096-89-8P,
3-Methoxy-N-phenethyl-4-(3-(pyrazin-2-yl)ureido)benzamide 457096-90-1P,
3-Methoxy-N-(3-phenylpropyl)-4-(3-(pyrazin-2-yl)ureido)benzamide 457096-92-3P, N-(2-(Benzenesulfonyl)ethyl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide 457096-95-6P, N-(4-Iodobenzyl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide 457096-97-8P 457096-99-0P
, 3-Methoxy-4-(3-(pyrazin-2-yl)ureido)-N-(2-(pyridin-4-yl)ethyl)benzamide 457097-01-7P, N-(1H-Benzimidazol-2-ylmethyl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-04-0P 457097-05-1P, 3-Methoxy-N-[3-(methylphenylamino)propyl]-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-08-4P 457097-10-8P, N-((3R)-1-Benzylpyrrolidin-3-

yl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-13-1P,
 N-((3S)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-16-4P, N-(2-Dimethylaminoethyl)-3-methoxy-N-methyl-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-18-6P,
 3-Methoxy-N-(3-methylaminopropyl)-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-21-1P, N-(3-Dimethylaminopropyl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-23-3P, N-(3-Dimethylaminopropyl)-3-methoxy-N-methyl-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-25-5P,
 3-Methoxy-N-(3-(morpholin-4-yl)propyl)-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-27-7P, 3-Methoxy-N-[3-(4-methylpiperazin-1-yl)propyl]-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-29-9P, [2-[3-Methoxy-4-(3-(pyrazin-2-yl)ureido)benzoylamino]ethyl]trimethylammonium chloride 457097-35-7P,
 N-Butyl-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-36-8P, N-Benzyl-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-37-9P,
 4-Methoxy-N-phenethyl-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-38-0P, 4-Methoxy-N-(3-phenylpropyl)-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-39-1P, N-(2-(Benzenesulfonyl)ethyl)-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-40-4P, 4-Methoxy-3-(3-(pyrazin-2-yl)ureido)-N-(2-(pyridin-2-yl)ethyl)benzamide 457097-41-5P,
 4-Methoxy-3-(3-(pyrazin-2-yl)ureido)-N-(2-(pyridin-4-yl)ethyl)benzamide 457097-42-6P, N-(1H-Benzimidazol-2-yl)methyl-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-43-7P, N-[2-(1H-Indol-3-yl)ethyl]-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-44-8P, 4-Methoxy-N-[3-(methylphenylamino)propyl]-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-45-9P 457097-46-0P, N-(2-Dimethylaminoethyl)-4-methoxy-N-methyl-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-47-1P,
 4-Methoxy-N-(3-methylaminopropyl)-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-48-2P, N-(3-Dimethylaminopropyl)-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-49-3P, N-(3-Dimethylaminopropyl)-4-methoxy-N-methyl-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-50-6P,
 4-Methoxy-N-[3-(4-methylpiperazin-1-yl)propyl]-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-51-7P, [2-[4-Methoxy-3-(3-(pyrazin-2-yl)ureido)benzoylamino]ethyl]trimethylammonium chloride 457097-52-8P,
 4-Methoxy-N-(3-(morpholin-4-yl)propyl)-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-57-3P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-(2-(pyridin-2-yl)ethyl)benzamide 457097-59-5P, N-(1-Benzylpiperidin-4-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-61-9P,
 N-(3-Dimethylaminopropyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-63-1P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-(3-(morpholin-4-yl)propyl)benzamide 457097-65-3P,
 N-(2-(Dimethylamino)-2-phenylethyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-68-6P, N-(2-(Dimethylamino)-1-phenylethyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-70-0P,
 N-(1-Azabicyclo[2.2.2]oct-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-71-1P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3R)-1-(pyridin-2-yl)methylpyrrolidin-3-yl)benzamide 457097-74-4P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3R)-1-methylpyrrolidin-3-yl)benzamide 457097-76-6P,
 N-((3R)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-77-7P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3R)-1-[(pyridin-4-yl)methyl]pyrrolidin-3-yl)benzamide 457097-79-9P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3S)-1-[(thiophen-2-yl)methyl]pyrrolidin-3-yl)benzamide 457097-81-3P,
 N-((3R)-1-Cyclohexylmethylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-83-5P, N-((3S)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-84-6P,
 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3S)-1-[(pyridin-2-yl)methyl]pyrrolidin-3-yl)benzamide 457097-86-8P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3S)-1-[(pyridin-3-yl)methyl]pyrrolidin-3-yl)benzamide 457097-87-9P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-

N-((3S)-1-[(pyridin-4-yl)methyl]pyrrolidin-3-yl)benzamide 457097-90-4P,
 N-((3S)-1-Cyclohexylmethylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-92-6P, N-((3S)-1-Benzylpyrrolidin-3-yl)-4-[3-(5-methylpyrazin-2-yl)ureido]-3-trifluoromethoxybenzamide 457097-97-1P, N-(1-Benzylpiperidin-4-ylmethyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-98-2P,
 N-[(3S)-1-(4-Fluorobenzyl)pyrrolidin-3-yl]-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457098-01-0P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzoic acid (3S)-1-benzylpyrrolidin-3-yl ester 457098-04-3P, N-((3S)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-trifluoromethylpyrazin-2-yl)ureido]benzamide 457098-08-7P,
 5-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-(2-(pyridin-2-yl)ethyl)-2-trifluoromethylbenzamide 457098-13-4P, 3-(3-Dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]benzoic acid 457098-17-8P,
 4-[3-(5-Methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzoic acid 457098-21-4P, 3-(3-Dimethylaminopropoxy)-4-[3-(5-n-methylpyrazin-2-yl)ureido]benzamide 457098-22-5P, 3-(3-Dimethylaminopropoxy)-N,N-dimethyl-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457098-23-6P,
 N-Benzyl-3-(3-dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457098-24-7P, N-Benzyl-3-(3-dimethylaminopropoxy)-N-methyl-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457098-25-8P,
 3-(3-Dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]-N-(2-(morpholin-4-yl)ethyl)benzamide 457098-26-9P, 3-(3-Dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]-N-[2-(1-methylpyrrolidin-2-yl)ethyl]benzamide 457098-27-0P, N-(2-Dimethylaminoethyl)-3-(3-dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457098-28-1P,
 N-((3S)-1-Benzylpyrrolidin-3-yl)-3-(3-dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457098-29-2P, 4-[3-(5-Methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide 457098-30-5P, N-Methyl-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide 457098-31-6P,
 N-Dimethyl-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide 457098-32-7P, N-Benzyl-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide 457098-33-8P,
 N-Benzyl-N-methyl-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide 457098-34-9P, 4-[3-(5-Methylpyrazin-2-yl)ureido]-N-(2-(morpholin-4-yl)ethyl)-3-(pyridin-3-ylmethoxy)benzamide 457098-35-0P,
 4-[3-(5-Methylpyrazin-2-yl)ureido]-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-3-(pyridin-3-ylmethoxy)benzamide 457098-36-1P, N-(2-Dimethylaminoethyl)-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide 457098-37-2P 457098-38-3P, 1-[2-(3-Dimethylaminopropoxy)-5-methylphenyl]-3-(pyrazin-2-yl)urea 457098-41-8P,
 1-[2-(2-Dimethylaminoethoxy)-5-methylphenyl]-3-(pyrazin-2-yl)urea 457098-42-9P, 1-[5-Methyl-2-(pyridin-3-ylmethoxy)phenyl]-3-(pyrazin-2-yl)urea 457098-43-0P, 1-[5-Methyl-2-[3-(2-oxopyrrolidin-1-yl)propoxy]phenyl]-3-(pyrazin-2-yl)urea 457098-44-1P, 1-[5-Methyl-2-(2-(morpholin-4-yl)ethoxy)phenyl]-3-(pyrazin-2-yl)urea 457098-45-2P, 1-[5-Methyl-2-(3-(morpholin-4-yl)propoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-46-3P,
 1-[2-(3-Dimethylaminopropoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-47-4P, 1-[5-Methyl-2-(2-(morpholin-4-yl)ethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-48-5P,
 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-2-ylmethoxy)phenyl]urea 457098-49-6P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-4-ylmethoxy)phenyl]urea 457098-50-9P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-3-ylmethoxy)phenyl]urea 457098-51-0P,
 1-[2-(2-Dimethylaminoethoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-52-1P, 1-(5-Methylpyrazin-2-yl)-3-[2-(pyridin-3-ylmethoxy)-5-trifluoromethylphenyl]urea 457098-53-2P, 1-[5-Methyl-2-(6-methylpyridin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea

457098-55-4P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(2-(pyridin-2-yl)ethoxy)phenyl]urea 457098-57-6P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(3-(pyridin-2-yl)propoxy)phenyl]urea 457098-59-8P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(3-(pyridin-4-yl)propoxy)phenyl]urea 457098-60-1P, 1-[2-[2-(Benzylmethylamino)ethoxy]-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-62-3P, 1-[5-Methyl-2-(1-methylpiperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-64-5P, 1-[2-[2-(4-Dimethylaminophenyl)ethoxy]-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-66-7P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(3-(pyridin-3-yl)propoxy)phenyl]urea 457098-68-9P, 1-[2-(2-(Dimethylamino)-1-(dimethylamino)methyl)ethoxy]-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-70-3P, 1-[5-Methyl-2-((2S)-1-methylpyrrolidin-2-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-72-5P, 1-[2-((2S)-1-Benzylpyrrolidin-2-ylmethoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-74-7P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(2-pyrrolidin-1-ylethoxy)phenyl]urea 457098-75-8P, 1-[5-Methyl-2-[2-(1-methylpyrrolidin-2-yl)ethoxy]phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-76-9P, 1-[2-(3H-Imidazol-4-ylmethoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-77-0P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(2-(pyridin-3-yl)ethoxy)phenyl]urea 457098-78-1P, 1-[5-Methyl-2-(3-(piperidin-1-yl)propoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-79-2P, 1-[5-Methyl-2-(1-methylpiperidin-4-yloxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-80-5P, 1-[2-(1-Benzylpiperidin-4-yloxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-81-6P, 1-[5-Methyl-2-((3S)-1-methylpiperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-82-7P, 1-[5-Methyl-2-((3R)-1-methylpiperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-84-9P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(1-(pyridin-3-yl)ethoxy)phenyl]urea 457098-85-0P, 1-[5-Methyl-2-(1-methylpiperidin-2-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-86-1P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(tetrahydrofuran-2-ylmethoxy)phenyl]urea 457098-87-2P, 1-[5-Methyl-2-(1-methylpiperidin-4-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-88-3P, 1-[5-Methyl-2-(1-methylpiperidin-3-yloxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-89-4P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(1,2,3,4-tetrahydroquinolin-3-ylmethoxy)phenyl]urea 457098-92-9P, 1-[2-(1-Ethyl-1,2,3,4-tetrahydroquinolin-3-ylmethoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-95-2P, 1-[5-Methyl-2-(1-methylpiperidin-3-ylmethoxy)phenyl]-3-(quinoxalin-2-yl)urea 457098-96-3P, 1-[5-Methyl-2-(pyridin-3-ylmethoxy)phenyl]-3-(quinoxalin-2-yl)urea 457098-99-6P, 1-[2-(2-(Aziridin-1-yl)ethoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457099-00-2P, 1-[2-(3-Dimethylaminobenzyloxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457099-01-3P, 1-[2-(1-Isopropylpyrrolidin-3-yloxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457099-02-4P, 1-[5-Methyl-2-(1-methylpyrrolidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-03-5P, 1-[5-Methyl-2-(piperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-04-6P, 1-[5-Fluoro-2-(pyridin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-05-7P, 1-[5-Fluoro-2-(1-methylpiperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-06-8P, 1-[5-Fluoro-2-(1-methylpiperidin-4-yloxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-07-9P, 1-[4-Fluoro-2-(pyridin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-08-0P, 1-[4-Fluoro-2-(1-methylpiperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-09-1P, 1-[4-Fluoro-2-(1-methylpiperidin-4-yloxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-10-4P, 1-[3,4-Difluoro-2-(pyridin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-11-5P,

1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-4-yloxy)phenyl]urea
 457099-12-6P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-3-
 yloxy)phenyl]urea 457099-15-9P, 1-(5-Methylpyrazin-2-yl)-3-[5-
 methyl-2-(pyridin-2-yloxy)phenyl]urea 457099-19-3P
 457099-21-7P, 1-(5,6-Dimethylpyrazin-2-yl)-3-(2-methoxy-5-
 methylphenyl)urea 457099-22-8P, 1-(2-Methoxy-5-methylphenyl)-3-
 (5-trifluoromethylpyrazin-2-yl)urea 457099-23-9P,
 1-(5,6-Diphenylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea
 457099-24-0P, 1-[3-Benzyl-5-(4-methoxyphenyl)pyrazin-2-yl]-3-(2-
 methoxy-5-methylphenyl)urea 457099-27-3P, 1-(6-Aminopyrazin-2-
 yl)-3-(2-methoxy-5-methylphenyl)urea 457099-28-4P,
 1-(6-Chloropyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea
 457099-30-8P, 1-(3,5-Dibromopyrazin-2-yl)-3-(2-methoxy-5-
 methylphenyl)urea 457099-34-2P, 1-(5-Aminomethylpyrazin-2-yl)-3-
 (2-methoxy-5-methylphenyl)urea 457099-35-3P,
 1-(2-Methoxy-5-methylphenyl)-3-(6-methoxypyrazin-2-yl)urea
 457099-37-5P, 1-(6-Benzyloxypyrazin-2-yl)-3-(2-methoxy-5-
 methylphenyl)urea 457099-40-0P, 1-(2-Methoxy-5-methylphenyl)-3-
 (5-methoxypyrazin-2-yl)urea 457099-41-1P, 1-(5-Ethynylpyrazin-2-
 yl)-3-(2-methoxy-5-methylphenyl)urea 457099-43-3P,
 1-(5-Ethylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea
 457099-44-4P, 1-(5-Cyanopyrazin-2-yl)-3-(2-methoxy-5-
 methylphenyl)urea 457099-46-6P, 1-[5-
 (Hydroxyphenylmethyl)pyrazin-2-yl]-3-(2-methoxy-5-methylphenyl)urea
 457099-47-7P, 1-(3-Bromo-5-phenylpyrazin-2-yl)-3-(2-methoxy-5-
 methylphenyl)urea 457099-48-8P, 1-(2-Methoxy-5-methylphenyl)-3-
 (5-phenylpyrazin-2-yl)urea 457099-49-9P 457099-50-2P,
 1-(3,6-Dimethylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea
 457099-53-5P, 1-(2-Methoxy-4-methoxymethylphenyl)-3-(5-methylpyrazin-2-
 yl)urea 457099-54-6P, 1-(4-Benzyloxymethyl-2-methoxyphenyl)-3-(5-
 methylpyrazin-2-yl)urea 457099-57-9P, 1-[4-[(Benzylamino)methyl]-2-
 methoxyphenyl]-3-(5-methylpyrazin-2-yl)urea 457099-60-4P,
 1-(2-Methoxy-4-[(methylamino)methyl]phenyl)-3-(5-methylpyrazin-2-yl)urea
 457099-65-9P, 1-(4-[(Dimethylamino)methyl]-2-methoxyphenyl)-3-(5-
 methylpyrazin-2-yl)urea 457099-68-2P, 1-[2-Methoxy-4-[(thiophen-2-
 ylmethyl)amino]methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-69-3P,
 1-[2-Methoxy-4-[(thiophen-3-ylmethyl)amino]methyl]phenyl]-3-(5-
 methylpyrazin-2-yl)urea 457099-70-6P, 1-[4-[(Furan-2-
 ylmethyl)amino]methyl]-2-methoxyphenyl]-3-(5-methylpyrazin-2-yl)urea
 457099-71-7P, 1-[4-[(Furan-3-ylmethyl)amino]methyl]-2-methoxyphenyl]-3-(5-
 methylpyrazin-2-yl)urea 457099-72-8P, 1-[2-Methoxy-4-[(2-
 methoxybenzylamino)methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea
 457099-73-9P, 1-[2-Methoxy-4-[(3-methoxybenzylamino)methyl]phenyl]-3-(5-
 methylpyrazin-2-yl)urea 457099-74-0P, 1-[2-Methoxy-4-[(4-
 methoxybenzylamino)methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea
 457099-75-1P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-
 yl)ureido]benzyl]acetamide 457099-76-2P, 2-Methoxy-N-[3-methoxy-4-[3-(5-
 methylpyrazin-2-yl)ureido]benzyl]acetamide 457099-77-3P,
 2-(Dimethylamino)-N-[3-methoxy-4-[3-(5-methylpyrazin-2-
 yl)ureido]benzyl]acetamide 457099-78-4P, N-[3-Methoxy-4-[3-(5-
 methylpyrazin-2-yl)ureido]benzyl]-2-(pyridin-2-yl)acetamide
 457099-79-5P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]-2-(4-
 methoxyphenyl)acetamide 457099-80-8P, N-[3-Methoxy-4-[3-(5-methylpyrazin-
 2-yl)ureido]benzyl]benzamide 457099-81-9P, Pyridine-2-carboxylic acid
 3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzylamide 457099-82-0P,
 N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]nicotinamide
 457099-83-1P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-
 yl)ureido]benzyl]isonicotinamide 457099-84-2P, Thiophene-2-carboxylic
 acid 3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzylamide
 457099-85-3P, 3-(Dimethylamino)-N-[3-methoxy-4-[3-(5-methylpyrazin-2-

yl)ureido]benzyl]benzamide 457099-86-4P 457099-87-5P 457099-88-6P,
 N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]benzenesulfonamide
 457099-89-7P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]-2-
 trifluoromethoxybenzenesulfonamide 457099-90-0P, 3-Methoxy-N-[3-methoxy-
 4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]benzenesulfonamide
 457099-91-1P, 4-Methoxy-N-[3-methoxy-4-[3-(5-methylpyrazin-2-
 yl)ureido]benzyl]benzenesulfonamide 457099-92-2P, Pyridine-2-sulfonic
 acid 3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzylamide
 457099-93-3P, N-(2-Methoxy-3-((2-(4-morpholinyl)ethyl)carbamoyl)phenyl)-N'-
 (2-pyrazinyl)urea 457099-94-4P, N-(2-Methoxy-3-((2-(1-methylpyrrolidin-2-
 yl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea 457099-95-5P,
 N-(4-((2-Chloroethyl)carbamoyl)-2-methoxyphenyl)-N'-(2-pyrazinyl)urea
 457099-96-6P, N-(2-Methoxy-4-((2-(4-morpholinyl)ethyl)carbamoyl)phenyl)-N'-
 (2-pyrazinyl)urea 457099-97-7P, N-(2-Methoxy-4-((2-(1-methylpyrrolidin-2-
 yl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea 457099-98-8P,
 N-(2-Methoxy-4-((2-((methylsulfonyl)amino)ethyl)carbamoyl)phenyl)-N'-(2-
 pyrazinyl)urea 457099-99-9P, N-(3-(Ethyl(methyl)carbamoyl)-2-
 methoxyphenyl)-N'-(2-pyrazinyl)urea 457100-00-4P
 , N-(2-Methoxy-5-methylphenyl)-N'-(4-pyrimidinyl)urea 457100-01-5P,
 N-(2-Methoxy-5-methylphenyl)-N'-(1,2,4-triazin-3-yl)urea
 457100-02-6P, N-(2-Methoxy-5-methylphenyl)-N'-(6-phenyl-2-
 pyrazinyl)urea 457100-03-7P, N-(2-Methoxy-5-methylphenyl)-N'-(2-
 pyrazinyl)urea 457100-04-8P, N-(4-((3-
 (Dimethylamino)propanoyl)amino)-2-methoxyphenyl)-N'-(2-pyrazinyl)urea
 458523-51-8P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3R)-1-
 [(thiophen-2-yl)methyl]pyrrolidin-3-yl)benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of aryl and heteroaryl urea selective Chk1 inhibitors for use
 as radiosensitizers and chemosensitizers for treating diseases and
 conditions related to DNA damage or lesions in DNA replication)


IT 457099-26-2P, 1-(6-Azidopyrazin-2-yl)-3-(2-methoxy-5-
 methylphenyl)urea 457099-29-5P, 1-(5-Bromopyrazin-2-yl)-3-(2-
 methoxy-5-methylphenyl)urea 457099-31-9P, 1-[5-(1,3-Dioxo-1,3-
 dihydroisoindol-2-ylmethyl)pyrazin-2-yl]-3-(2-methoxy-5-methylphenyl)urea
 457099-45-5P, 1-(5-Benzoylpyrazin-2-yl)-3-(2-methoxy-5-
 methylphenyl)urea

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)


(intermediate; prepn. of aryl and heteroaryl urea selective Chk1
 inhibitors for use as radiosensitizers and chemosensitizers for
 treating diseases and conditions related to DNA damage or lesions in
 DNA replication)

RN 457099-26-2 HCAPLUS


CN Urea, N-(6-azidopyrazinyl)-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA INDEX
 NAME)




RN 457099-29-5 HCAPLUS
CN Urea, N-(5-bromopyrazinyl)-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA INDEX NAME)



RN 457099-31-9 HCAPLUS
CN Urea, N-[5-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]pyrazinyl]-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA INDEX NAME)



RN 457099-45-5 HCAPLUS
CN Urea, N-(5-benzoylpyrazinyl)-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA INDEX NAME)



IT 457096-79-6P, N-(4-((3-(Cyclohexyl(methyl)amino)propanoyl)amino)-2-methoxyphenyl)-N'-(2-pyrazinyl)urea 457096-80-9P, 3-(Cyclohexyl(methyl)amino)-N-[3-methoxy-4-(3-(pyrazin-2-yl)ureido)phenyl]propionamide trifluoroacetate 457096-81-0P, 3-(Cyclopentylamino)-N-[3-methoxy-4-(3-(pyrazin-2-yl)ureido)phenyl]propionamide 457096-97-8P 457096-99-0P, 3-Methoxy-4-(3-(pyrazin-2-yl)ureido)-N-(2-(pyridin-4-yl)ethyl)benzamide 457097-08-4P 457097-10-8P, N-((3R)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-13-1P, N-((3S)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-40-4P, 4-Methoxy-3-(3-(pyrazin-2-yl)ureido)-N-(2-(pyridin-2-yl)ethyl)benzamide 457097-41-5P, 4-Methoxy-3-(3-(pyrazin-2-yl)ureido)-N-(2-(pyridin-4-yl)ethyl)benzamide 457097-45-9P 457097-57-3P, 3-Methoxy-4-[3-(5-

methylpyrazin-2-yl)ureido]-N-(2-(pyridin-2-yl)ethyl)benzamide
 457097-76-6P, N-((3R)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-83-5P,
 N-((3S)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-92-6P, N-((3S)-1-Benzylpyrrolidin-3-yl)-4-[3-(5-methylpyrazin-2-yl)ureido]-3-trifluoromethoxybenzamide
 457097-98-2P, N-[(3S)-1-(4-Fluorobenzyl)pyrrolidin-3-yl]-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457098-04-3P,
 N-((3S)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-trifluoromethylpyrazin-2-yl)ureido]benzamide 457098-28-1P, N-((3S)-1-Benzylpyrrolidin-3-yl)-3-(3-dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide
 457098-37-2P 457098-38-3P, 1-[2-(3-Dimethylaminopropoxy)-5-methylphenyl]-3-(pyrazin-2-yl)urea 457098-41-8P,
 1-[2-(2-Dimethylaminoethoxy)-5-methylphenyl]-3-(pyrazin-2-yl)urea 457098-42-9P, 1-[5-Methyl-2-(pyridin-3-ylmethoxy)phenyl]-3-(pyrazin-2-yl)urea 457098-43-0P, 1-[5-Methyl-2-[3-(2-oxopyrrolidin-1-yl)propoxy]phenyl]-3-(pyrazin-2-yl)urea
 457098-44-1P, 1-[5-Methyl-2-(2-(morpholin-4-yl)ethoxy)phenyl]-3-(pyrazin-2-yl)urea 457098-45-2P, 1-[5-Methyl-2-(3-(morpholin-4-yl)propoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-46-3P,
 1-[2-(3-Dimethylaminopropoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-47-4P, 1-[5-Methyl-2-(2-(morpholin-4-yl)ethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-48-5P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-2-ylmethoxy)phenyl]urea 457098-49-6P,
 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-4-ylmethoxy)phenyl]urea 457098-50-9P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-3-ylmethoxy)phenyl]urea 457098-51-0P, 1-[2-(2-Dimethylaminoethoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-53-2P,
 1-[5-Methyl-2-(6-methylpyridin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-55-4P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(2-(pyridin-2-yl)ethoxy)phenyl]urea 457098-57-6P,
 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(3-(pyridin-2-yl)propoxy)phenyl]urea 457098-59-8P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(3-(pyridin-4-yl)propoxy)phenyl]urea 457098-60-1P,
 1-[2-[2-(Benzylmethylamino)ethoxy]-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-62-3P, 1-[5-Methyl-2-(1-methylpiperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-64-5P,
 1-[2-[2-(4-Dimethylaminophenyl)ethoxy]-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-66-7P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(3-(pyridin-3-yl)propoxy)phenyl]urea 457098-68-9P,
 1-[2-(2-(Dimethylamino)-1-((dimethylamino)methyl)ethoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-70-3P, 1-[5-Methyl-2-((2S)-1-methylpyrrolidin-2-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea
 457098-72-5P, 1-[2-((2S)-1-Benzylpyrrolidin-2-ylmethoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-74-7P,
 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(2-pyrrolidin-1-ylethoxy)phenyl]urea 457098-75-8P, 1-[5-Methyl-2-[2-(1-methylpyrrolidin-2-yl)ethoxy]phenyl]-3-(5-methylpyrazin-2-yl)urea
 457098-76-9P, 1-[2-(3H-Imidazol-4-ylmethoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-77-0P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(2-(pyridin-3-yl)ethoxy)phenyl]urea 457098-78-1P,
 1-[5-Methyl-2-(3-(piperidin-1-yl)propoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-79-2P, 1-[5-Methyl-2-(1-methylpiperidin-4-yloxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-80-5P,
 1-[2-(1-Benzylpiperidin-4-yloxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-81-6P, 1-[5-Methyl-2-((3S)-1-methylpiperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-82-7P,
 1-[5-Methyl-2-((3R)-1-methylpiperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-84-9P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(1-(pyridin-3-yl)ethoxy)phenyl]urea 457098-85-0P,

1-[5-Methyl-2-(1-methylpiperidin-2-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-86-1P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(tetrahydrofuran-2-ylmethoxy)phenyl]urea 457098-87-2P, 1-[5-Methyl-2-(1-methylpiperidin-4-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-88-3P, 1-[5-Methyl-2-(1-methylpiperidin-3-yloxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-89-4P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(1,2,3,4-tetrahydroquinolin-3-ylmethoxy)phenyl]urea 457098-92-9P, 1-[2-(1-Ethyl-1,2,3,4-tetrahydroquinolin-3-ylmethoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-95-2P, 1-[5-Methyl-2-(1-methylpiperidin-3-ylmethoxy)phenyl]-3-(quinoxalin-2-yl)urea 457098-96-3P, 1-[5-Methyl-2-(pyridin-3-ylmethoxy)phenyl]-3-(quinoxalin-2-yl)urea 457098-99-6P, 1-[2-(2-(Aziridin-1-yl)ethoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457099-00-2P, 1-[2-(3-Dimethylaminobenzoyloxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457099-01-3P, 1-[2-(1-Isopropylpyrrolidin-3-yloxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457099-02-4P, 1-[5-Methyl-2-(1-methylpyrrolidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-03-5P, 1-[5-Methyl-2-(piperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-11-5P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-4-yloxy)phenyl]urea 457099-12-6P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-3-yloxy)phenyl]urea 457099-15-9P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-2-yloxy)phenyl]urea 457099-19-3P 457099-21-7P, 1-(5,6-Dimethylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-22-8P, 1-(2-Methoxy-5-methylphenyl)-3-(5-trifluoromethylpyrazin-2-yl)urea 457099-23-9P, 1-(5,6-Diphenylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-24-0P, 1-[3-Benzyl-5-(4-methoxyphenyl)pyrazin-2-yl]-3-(2-methoxy-5-methylphenyl)urea 457099-27-3P, 1-(6-Aminopyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-28-4P, 1-(6-Chloropyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-30-8P, 1-(3,5-Dibromopyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-34-2P, 1-(5-Aminomethylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-35-3P, 1-(2-Methoxy-5-methylphenyl)-3-(6-methoxypyrazin-2-yl)urea 457099-37-5P, 1-(6-Benzoyloxy pyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-40-0P, 1-(2-Methoxy-5-methylphenyl)-3-(5-methoxypyrazin-2-yl)urea 457099-41-1P, 1-(5-Ethynylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-43-3P, 1-(5-Ethylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-44-4P, 1-(5-Cyanopyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-46-6P, 1-[5-(Hydroxyphenylmethyl)pyrazin-2-yl]-3-(2-methoxy-5-methylphenyl)urea 457099-47-7P, 1-(3-Bromo-5-phenylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-48-8P, 1-(2-Methoxy-5-methylphenyl)-3-(5-phenylpyrazin-2-yl)urea 457099-49-9P 457099-50-2P, 1-(3,6-Dimethylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457100-02-6P, N-(2-Methoxy-5-methylphenyl)-N'-(6-phenyl-2-pyrazinyl)urea 457100-03-7P, N-(2-Methoxy-5-methylphenyl)-N'-(2-pyrazinyl)urea 457100-04-8P, N-(4-((3-(Dimethylamino)propanoyl)amino)-2-methoxyphenyl)-N'-(2-pyrazinyl)urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of aryl and heteroaryl urea selective Chk1 inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)

RN 457096-79-6 HCAPLUS

CN Propanamide, 3-(cyclohexylmethylamino)-N-[3-methoxy-4-

Patel 10/087,715

[[(pyrazinylamino) carbonyl] amino] phenyl] - (9CI) (CA INDEX NAME)




RN 457096-80-9 HCAPLUS

CN Propanamide, 3-(cyclohexylmethylamino)-N-[3-methoxy-4-
[[(pyrazinylamino) carbonyl] amino] phenyl] -, trifluoroacetate (9CI) (CA
INDEX NAME)

CM 1

CRN 457096-79-6


CMF C22 H30 N6 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 457096-81-0 HCAPLUS

CN Propanamide, 3-(cyclopentylamino)-N-[3-methoxy-4-
[[(pyrazinylamino) carbonyl] amino] phenyl] - (9CI) (CA INDEX NAME)




RN 457096-97-8 HCAPLUS

CN Benzamide, 3-methoxy-4-[[(pyrazinylamino)carbonyl]amino]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 457096-99-0 HCAPLUS

CN Benzamide, 3-methoxy-4-[[(pyrazinylamino)carbonyl]amino]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 457097-08-4 HCAPLUS

CN Benzamide, 3-methoxy-N-[1-(phenylmethyl)-3-pyrrolidinyl]-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




PAGE 1-A




RN 457097-10-8 HCAPLUS
 CN Benzamide, 3-methoxy-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-4-
 [[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 457097-13-1 HCAPLUS
 CN Benzamide, 3-methoxy-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]-4-
 [[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 457097-40-4 HCAPLUS
 CN Benzamide, 4-methoxy-3-[[pyrazinylamino]carbonyl]amino]-N-[2-(2-
 pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 457097-41-5 HCAPLUS

CN Benzamide, 4-methoxy-3-[[(pyrazinylamino) carbonyl] amino] -N- [2- (4-
pyridinyl) ethyl] - (9CI) (CA INDEX NAME)




RN 457097-45-9 HCAPLUS

CN Benzamide, 4-methoxy-N- [1- (phenylmethyl) -3- pyrrolidinyl] -3-
[[(pyrazinylamino) carbonyl] amino] - (9CI) (CA INDEX NAME)



RN 457097-57-3 HCAPLUS


CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl) amino] carbonyl] amino] -N- [2- (2-
pyridinyl) ethyl] - (9CI) (CA INDEX NAME)



RN 457097-76-6 HCAPLUS

CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl) amino] carbonyl] amino] -N- [(3R) -
1- (phenylmethyl) -3- pyrrolidinyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457097-83-5 HCAPLUS

CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457097-92-6 HCAPLUS

CN Benzamide, 4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457097-98-2 HCAPLUS

CN Benzamide, N-[(3S)-1-[(4-fluorophenyl)methyl]-3-pyrrolidinyl]-3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457098-04-3 HCAPLUS

CN Benzamide, 3-methoxy-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]-4-[[[(5-(trifluoromethyl)pyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 457098-28-1 HCAPLUS

CN Benzamide, 3-[3-(dimethylamino)propoxy]-4-[[[(5-

methylpyrazinyl) amino] carbonyl] amino] -N- [(3S) -1- (phenylmethyl) -3-
pyrrolidiny] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457098-37-2 HCAPLUS


CN Benzamide, 4-[[[(5-methylpyrazinyl) amino] carbonyl] amino] -N- [(3S) -1-
(phenylmethyl) -3-pyrrolidiny] -3-(3-pyridinylmethoxy) - (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 457098-38-3 HCAPLUS

CN Urea, N- [2- [3- (dimethylamino) propoxy] -5-methylphenyl] -N'-pyrazinyl- (9CI)
(CA INDEX NAME)




RN 457098-41-8 HCAPLUS

CN Urea, N-[2-[2-(dimethylamino)ethoxy]-5-methylphenyl]-N'-pyrazinyl- (9CI)
(CA INDEX NAME)




RN 457098-42-9 HCAPLUS

CN Urea, N-[5-methyl-2-(3-pyridinylmethoxy)phenyl]-N'-pyrazinyl- (9CI) (CA
INDEX NAME)




RN 457098-43-0 HCAPLUS

CN Urea, N-[5-methyl-2-[3-(2-oxo-1-pyrrolidinyl)propoxy]phenyl]-N'-pyrazinyl-
(9CI) (CA INDEX NAME)




RN 457098-44-1 HCAPLUS

CN Urea, N-[5-methyl-2-[2-(4-morpholinyl)ethoxy]phenyl]-N'-pyrazinyl- (9CI)
(CA INDEX NAME)




RN 457098-45-2 HCAPLUS

CN Urea, N-[5-methyl-2-[3-(4-morpholinyl)propoxy]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)





RN 457098-46-3 HCAPLUS

CN Urea, N-[2-[3-(dimethylamino)propoxy]-5-methylphenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)




RN 457098-47-4 HCAPLUS

CN Urea, N-[5-methyl-2-[2-(4-morpholinyl)ethoxy]phenyl]-N'-(5-methylpyrazinyl)-(9CI) (CA INDEX NAME)




RN 457098-48-5 HCAPLUS

CN Urea, N-(5-methylpyrazinyl)-N'-[5-methyl-2-(2-pyridinylmethoxy)phenyl]-(9CI) (CA INDEX NAME)




RN 457098-49-6 HCAPLUS

CN Urea, N-(5-methylpyrazinyl)-N'-[5-methyl-2-(4-pyridinylmethoxy)phenyl]-(9CI) (CA INDEX NAME)




RN 457098-50-9 HCAPLUS

CN Urea, N-(5-methylpyrazinyl)-N'-[5-methyl-2-(3-pyridinylmethoxy)phenyl]-
(9CI) (CA INDEX NAME)




RN 457098-51-0 HCAPLUS

CN Urea, N-[2-[2-(dimethylamino)ethoxy]-5-methylphenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)





RN 457098-53-2 HCAPLUS

CN Urea, N-[5-methyl-2-[(6-methyl-3-pyridinyl)methoxy]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)





RN 457098-55-4 HCAPLUS

CN Urea, N-(5-methylpyrazinyl)-N'-[5-methyl-2-[2-(2-pyridinyl)ethoxy]phenyl]-
(9CI) (CA INDEX NAME)




RN 457098-57-6 HCAPLUS

CN Urea, N-(5-methylpyrazinyl)-N'-[5-methyl-2-[3-(2-pyridinyl)propoxy]phenyl]-
(9CI) (CA INDEX NAME)




RN 457098-59-8 HCAPLUS

CN Urea, N-(5-methylpyrazinyl)-N'-[5-methyl-2-[3-(4-pyridinyl)propoxy]phenyl]-
(9CI) (CA INDEX NAME)




RN 457098-60-1 HCAPLUS

CN Urea, N-[5-methyl-2-[2-[methyl(phenylmethyl)amino]ethoxy]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)





RN 457098-62-3 HCAPLUS

CN Urea, N-[5-methyl-2-[(1-methyl-3-piperidinyl)methoxy]phenyl]-N'-(5-methylpyrazinyl) - (9CI) (CA INDEX NAME)




RN 457098-64-5 HCAPLUS

CN Urea, N-[2-[2-[4-(dimethylamino)phenyl]ethoxy]-5-methylphenyl]-N'-(5-methylpyrazinyl) - (9CI) (CA INDEX NAME)




RN 457098-66-7 HCAPLUS

CN Urea, N-(5-methylpyrazinyl)-N'-[5-methyl-2-[3-(3-pyridinyl)propoxy]phenyl] - (9CI) (CA INDEX NAME)



RN 457098-68-9 HCAPLUS


CN Urea, N-[2-[2-(dimethylamino)-1-[(dimethylamino)methyl]ethoxy]-5-methylphenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)



RN 457098-70-3 HCAPLUS

CN Urea, N-[5-methyl-2-[[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 457098-72-5 HCAPLUS

CN Urea, N-[5-methyl-2-[[[(2S)-1-(phenylmethyl)-2-pyrrolidinyl]methoxy]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 457098-74-7 HCAPLUS
 CN Urea, N-(5-methylpyrazinyl)-N'-[5-methyl-2-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 457098-75-8 HCAPLUS
 CN Urea, N-[5-methyl-2-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)





RN 457098-76-9 HCAPLUS
 CN Urea, N-[2-(1H-imidazol-4-ylmethoxy)-5-methylphenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)




RN 457098-77-0 HCAPLUS

CN Urea, N-(5-methylpyrazinyl)-N'-[5-methyl-2-[2-(3-pyridinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 457098-78-1 HCAPLUS

CN Urea, N-[5-methyl-2-[3-(1-piperidinyl)propoxy]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)




RN 457098-79-2 HCAPLUS

CN Urea, N-[5-methyl-2-[(1-methyl-4-piperidinyl)oxy]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)



RN 457098-80-5 HCAPLUS


CN Urea, N-[5-methyl-2-[[1-(phenylmethyl)-4-piperidinyloxy]phenyl]-N'-(5-methylpyrazinyl)-(9CI) (CA INDEX NAME)



RN 457098-81-6 HCAPLUS

CN Urea, N-[5-methyl-2-[[[(3S)-1-methyl-3-piperidinyloxy]methoxy]phenyl]-N'-(5-methylpyrazinyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457098-82-7 HCAPLUS



CN Urea, N-[5-methyl-2-[[[(3R)-1-methyl-3-piperidinyloxy]methoxy]phenyl]-N'-(5-methylpyrazinyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 457098-84-9 HCAPLUS

CN Urea, N-(5-methylpyrazinyl)-N'-[5-methyl-2-[(1-(3-pyridinyl)ethoxy)phenyl]-
(9CI) (CA INDEX NAME)




RN 457098-85-0 HCAPLUS

CN Urea, N-[5-methyl-2-[(1-methyl-2-piperidinyl)methoxy]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)




RN 457098-86-1 HCAPLUS

CN Urea, N-(5-methylpyrazinyl)-N'-[5-methyl-2-[(tetrahydro-2-furanyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 457098-87-2 HCAPLUS

CN Urea, N-[5-methyl-2-[(1-methyl-4-piperidinyl)methoxy]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)




RN 457098-88-3 HCAPLUS

CN Urea, N-[5-methyl-2-[(1-methyl-3-piperidinyl)oxy]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)




RN 457098-89-4 HCAPLUS

CN Urea, N-(5-methylpyrazinyl)-N'-[5-methyl-2-[(1,2,3,4-tetrahydro-3-quinolinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 457098-92-9 HCAPLUS

CN Urea, N-[2-[(1-ethyl-1,2,3,4-tetrahydro-3-quinolinyl)methoxy]-5-methylphenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)




RN 457098-95-2 HCAPLUS

CN Urea, N-[5-methyl-2-[(1-methyl-3-piperidiny)methoxy]phenyl]-N'-2-quinoxaliny- (9CI) (CA INDEX NAME)




RN 457098-96-3 HCAPLUS

CN Urea, N-[5-methyl-2-(3-pyridinylmethoxy)phenyl]-N'-2-quinoxaliny- (9CI) (CA INDEX NAME)




RN 457098-99-6 HCAPLUS

CN Urea, N-[2-[2-(1-aziridinyl)ethoxy]-5-methylphenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)




RN 457099-00-2 HCAPLUS

CN Urea, N-[2-[[3-(dimethylamino)phenyl]methoxy]-5-methylphenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)



RN 457099-01-3 HCAPLUS


CN Urea, N-[5-methyl-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)



RN 457099-02-4 HCAPLUS


CN Urea, N-[5-methyl-2-[(1-methyl-3-pyrrolidinyl)methoxy]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)

methylpyrazinyl) - (9CI) (CA INDEX NAME)




RN 457099-03-5 HCAPLUS

CN Urea, N-[5-methyl-2-(3-piperidinylmethoxy)phenyl]-N'-(5-methylpyrazinyl)-
(9CI) (CA INDEX NAME)




RN 457099-11-5 HCAPLUS

CN Urea, N-(5-methylpyrazinyl)-N'-[5-methyl-2-(4-pyridinyloxy)phenyl]- (9CI)
(CA INDEX NAME)




RN 457099-12-6 HCAPLUS


CN Urea, N-(5-methylpyrazinyl)-N'-[5-methyl-2-(3-pyridinyloxy)phenyl]- (9CI)
(CA INDEX NAME)




RN 457099-15-9 HCAPLUS
 CN Urea, N-(5-methylpyrazinyl)-N'-[5-methyl-2-(2-pyridinyloxy)phenyl]- (9CI)
 (CA INDEX NAME)




RN 457099-19-3 HCAPLUS
 CN Urea, N-(2-methoxy-5-methylphenyl)-N'-(5-methylpyrazinyl)- (9CI) (CA
 INDEX NAME)




RN 457099-21-7 HCAPLUS
 CN Urea, N-(5,6-dimethylpyrazinyl)-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA
 INDEX NAME)




RN 457099-22-8 HCAPLUS
 CN Urea, N-(2-methoxy-5-methylphenyl)-N'-[5-(trifluoromethyl)pyrazinyl]-
 (9CI) (CA INDEX NAME)




RN 457099-23-9 HCAPLUS
CN Urea, N-(5,6-diphenylpyrazinyl)-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA INDEX NAME)




RN 457099-24-0 HCAPLUS
CN Urea, N-(2-methoxy-5-methylphenyl)-N'-[5-(4-methoxyphenyl)-3-(phenylmethyl)pyrazinyl]- (9CI) (CA INDEX NAME)




RN 457099-27-3 HCAPLUS
CN Urea, N-(6-aminopyrazinyl)-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA INDEX NAME)




RN 457099-28-4 HCAPLUS
CN Urea, N-(6-chloropyrazinyl)-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA INDEX NAME)




RN 457099-30-8 HCAPLUS
 CN Urea, N-(3,5-dibromopyrazinyl)-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA INDEX NAME)




RN 457099-34-2 HCAPLUS
 CN Urea, N-[5-(aminomethyl)pyrazinyl]-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA INDEX NAME)




RN 457099-35-3 HCAPLUS
 CN Urea, N-(2-methoxy-5-methylphenyl)-N'-(6-methoxypyrazinyl)- (9CI) (CA INDEX NAME)




RN 457099-37-5 HCAPLUS
 CN Urea, N-(2-methoxy-5-methylphenyl)-N'-[6-(phenylmethoxy)pyrazinyl]- (9CI) (CA INDEX NAME)




RN 457099-40-0 HCAPLUS
 CN Urea, N-(2-methoxy-5-methylphenyl)-N'-(5-methoxypyrazinyl)- (9CI) (CA INDEX NAME)




RN 457099-41-1 HCAPLUS
 CN Urea, N-(5-ethynylpyrazinyl)-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA INDEX NAME)




RN 457099-43-3 HCAPLUS
 CN Urea, N-(5-ethylpyrazinyl)-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA INDEX NAME)




RN 457099-44-4 HCAPLUS
 CN Urea, N-(5-cyanopyrazinyl)-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA INDEX NAME)




RN 457099-46-6 HCAPLUS
 CN Urea, N-[5-(hydroxyphenylmethyl)pyrazinyl]-N'-(2-methoxy-5-methylphenyl)-
 (9CI) (CA INDEX NAME)




RN 457099-47-7 HCAPLUS
 CN Urea, N-(3-bromo-5-phenylpyrazinyl)-N'-(2-methoxy-5-methylphenyl)- (9CI)
 (CA INDEX NAME)




RN 457099-48-8 HCAPLUS
 CN Urea, N-(2-methoxy-5-methylphenyl)-N'-(5-phenylpyrazinyl)- (9CI) (CA
 INDEX NAME)




RN 457099-49-9 HCAPLUS
 CN Urea, N-(2-methoxy-5-methylphenyl)-N'-2-quinoxaliny- (9CI) (CA INDEX
 NAME)




RN 457099-50-2 HCAPLUS
 CN Urea, N-(3,6-dimethylpyrazinyl)-N'-(2-methoxy-5-methylphenyl)- (9CI) (CA INDEX NAME)




RN 457100-02-6 HCAPLUS
 CN Urea, N-(2-methoxy-5-methylphenyl)-N'-(6-phenylpyrazinyl)- (9CI) (CA INDEX NAME)



RN 457100-03-7 HCAPLUS
 CN Urea, N-(2-methoxy-5-methylphenyl)-N'-pyrazinyl- (9CI) (CA INDEX NAME)



RN 457100-04-8 HCAPLUS
 CN Propanamide, 3-(dimethylamino)-N-[3-methoxy-4-[[pyrazinylamino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

4 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
ENTER ANSWER NUMBER OR RANGE (1):end

=> d .ca hitstr l18 1-4

L18 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:695962 HCAPLUS

DOCUMENT NUMBER: 137:232680

TITLE: Preparation of aryl and heteroaryl urea selective
Chk1 inhibitors for use as radiosensitizers
and chemosensitizers for treating diseases and
conditions related to DNA damage or lesions in DNA
replication

INVENTOR(S): Keegan, Kathleen S.; Kesicki, Edward A.; Gaudino, John
Joseph; Cook, Adam Wade; Cowen, Scott Douglas;
Burgess, Laurence Edward

PATENT ASSIGNEE(S): Icos Corporation, USA

SOURCE: PCT Int. Appl., 236 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002070494	A1	20020912	WO 2002-US6452	20020301
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-273124P P 20010302

OTHER SOURCE(S): MARPAT 137:232680

AB Aryl- and heteroaryl substituted urea compds. (W'NHC(:Y')N(R13)Z'; 1)
useful in the treatment of diseases and conditions related to DNA damage
or lesions in DNA replication are disclosed. In 1, W' is a six-membered
arom. ring contg. at least 2 nitrogen atoms (e.g. pyrazinyl, pyrimidinyl,
pyridazinyl, 1,2,4-triazinyl, quinoxaliny) and optionally substituted as
defined in the claims, Z' is a five- or six membered arom. or heteroarom.

ring as defined in the claims, Y' is O or S. The first claim contains a much more general formula $WX_1C(:Y)X_2Z$ (e.g. $X_1 = \text{null, O, S, CH}_2, \text{NR}_1$; $X_2 = \text{O, S, NR}_1$) but emphasis is on 1. Methods of making the compds., and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are described. Although the methods of prepn. are not claimed, about 200 example prepn. are included. N-(2-methoxy-5-methylphenyl)-N'-(2-pyrazinyl)urea and N-(4-chloro-2-methoxyphenyl)-N'-(2-pyrazinyl)urea enhanced the killing of various human cells by 5-fluorouracil from 2- to 10-fold; in HeLa cells, these same compds. enhanced killing by irradiation 2-3 fold.

- IC ICM C07D241-20
- ICS C07D401-12; C07D403-12; C07D241-54; A61K031-4965; A61K031-498; A61P035-00; C07D405-12; C07D251-22; C07D231-40; C07D239-46; C07D253-06; C07D239-42; C07D257-06; C07D213-75; C07D277-48
- CC 28-19 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
- ST aryl heteroaryl urea prepn selective **Chk1** inhibitor
radiosensitizer chemosensitizer; pyrazinyl urea prepn selective **Chk1** inhibitor radiosensitizer chemosensitizer; pyrimidinyl urea prepn selective **Chk1** inhibitor radiosensitizer chemosensitizer; pyridazinyl urea prepn selective **Chk1** inhibitor radiosensitizer chemosensitizer; triazinyl urea prepn selective **Chk1** inhibitor radiosensitizer chemosensitizer; quinoxalinyl urea prepn selective **Chk1** inhibitor radiosensitizer chemosensitizer; antitumor agent
aryl heteroaryl urea selective **Chk1** inhibitor prepn
- IT **Neoplasm**
(ACTH-producing; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Bone, **neoplasm**
(Ewing's sarcoma; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Sarcoma
(Kaposi's; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Skin, **neoplasm**
(T-cell lymphoma; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Granulomatous disease
(Wegener's granulomatosis; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Kidney, **neoplasm**
(Wilms'; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Penis
(acuminate wart; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA

- IT damage or lesions in DNA replication)
- IT Leukemia
 (acute lymphocytic; prepn. of aryl and heteroaryl urea selective
 Chk1 inhibitors for use as radiosensitizers and
 chemosensitizers for treating diseases and conditions related to DNA
 damage or lesions in DNA replication)
- IT Leukemia
 (acute nonlymphocytic; prepn. of aryl and heteroaryl urea selective
 Chk1 inhibitors for use as radiosensitizers and
 chemosensitizers for treating diseases and conditions related to DNA
 damage or lesions in DNA replication)
- IT Alkylation
 (agents; in combination with aryl and heteroaryl urea selective
 Chk1 inhibitors for treating diseases and conditions related to
 DNA damage or lesions in DNA replication)
- IT Nutrients
 (anti-; in combination with aryl and heteroaryl urea selective
 Chk1 inhibitors for treating diseases and conditions related to
 DNA damage or lesions in DNA replication)
- IT Chemotherapy
 (aryl and heteroaryl urea selective **Chk1** inhibitors for use
 as sensitizers in)
- IT Astrocyte
 (astrocytoma; prepn. of aryl and heteroaryl urea selective **Chk1**
 inhibitors for use as radiosensitizers and chemosensitizers for
 treating diseases and conditions related to DNA damage or lesions in
 DNA replication)
- IT Lung, **neoplasm**
 Mouth
 Ovary, **neoplasm**
 (carcinoma; prepn. of aryl and heteroaryl urea selective
 Chk1 inhibitors for use as radiosensitizers and
 chemosensitizers for treating diseases and conditions related to DNA
 damage or lesions in DNA replication)
- IT Uterus, **neoplasm**
 (cervix, **carcinoma**; prepn. of aryl and heteroaryl urea
 selective **Chk1** inhibitors for use as radiosensitizers and
 chemosensitizers for treating diseases and conditions related to DNA
 damage or lesions in DNA replication)
- IT Drugs
 (chemosensitizers and radiosensitizers; prepn. of aryl and heteroaryl
 urea selective **Chk1** inhibitors for use as)
- IT Leukemia
 (chronic lymphocytic; prepn. of aryl and heteroaryl urea selective
 Chk1 inhibitors for use as radiosensitizers and
 chemosensitizers for treating diseases and conditions related to DNA
 damage or lesions in DNA replication)
- IT Leukemia
 (chronic myelocytic; prepn. of aryl and heteroaryl urea selective
 Chk1 inhibitors for use as radiosensitizers and
 chemosensitizers for treating diseases and conditions related to DNA
 damage or lesions in DNA replication)
- IT Intestine, **neoplasm**
 (colon; prepn. of aryl and heteroaryl urea selective **Chk1**
 inhibitors for use as radiosensitizers and chemosensitizers for
 treating diseases and conditions related to DNA damage or lesions in
 DNA replication)
- IT Intestine, **neoplasm**
 (colorectal, and related polyps; prepn. of aryl and heteroaryl urea
 selective **Chk1** inhibitors for use as radiosensitizers and

- chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Intestine, **neoplasm**
(colorectal; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Mammary gland
(ductal **carcinoma**; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Lymphoma
(effusion; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Uterus, disease
(endometrium, hyperplasia; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT **Neoplasm**
(epithelial, primary peritoneal; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Neuroglia
(glioma; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Leukemia
(hairy-cell; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Blood vessel, **neoplasm**
(hemangiopericytoma; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Gamma ray
IR radiation
Light
Microwave
UV radiation
X-ray
(in combination with aryl and heteroaryl urea selective **Chk1** inhibitors for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Antibodies
Cytokines
Growth factors, animal
Hemopoietins
Lymphokines
Radionuclides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in combination with aryl and heteroaryl urea selective **Chk1** inhibitors for treating diseases and conditions related to DNA damage

- or lesions in DNA replication)

IT Skin, **neoplasm**
 (keratinocyte; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Thymus gland
 (lymphoma; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Mesothelium
 (mesothelioma; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT **Neoplasm**
 (metastasis; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT **Carcinoma**
 (myxoid and round cell; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Lymph node
 (**neoplasm**, metastasis; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Bladder
 Gallbladder
 Head
 Mammary gland
 Neck, anatomical
 Pleura
 Prostate gland
 Trophoblast
 Vagina
 (**neoplasm**; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Nerve, **neoplasm**
 (neuroblastoma; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Lymphoma
 (non-Hodgkin's; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Hormones, animal, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (or antagonist thereof; in combination with aryl and heteroaryl urea selective **Chk1** inhibitors for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Bone, **neoplasm**

- (osteomas; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Bone, **neoplasm**
(osteosarcoma; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Ovary, **neoplasm**
(ovarian follicle; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Radiosensitizers, biological
(pharmaceutical; aryl and heteroaryl urea selective **Chk1** inhibitors for use as sensitizers in)
- IT Radiosensitizers, biological
(pharmaceutical; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as)
- IT Human
(prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers)
- IT Adrenal cortex, **neoplasm**
Antirheumatic agents
Antitumor agents
Ascitic fluid
Brain, **neoplasm**
Hodgkin's disease
Leukemia
Liver, **neoplasm**
Lymphoma
Melanoma
Multiple myeloma
Ovary, **neoplasm**
Pancreas, **neoplasm**
Psoriasis
Rheumatoid arthritis
Stomach, **neoplasm**
Testis, **neoplasm**
Thyroid gland, **neoplasm**
Uterus, **neoplasm**
Vitiligo
(prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Kidney, **neoplasm**
(renal cell **carcinoma**; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Eye, **neoplasm**
(retinoblastoma; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Lung, **neoplasm**
(small-cell **carcinoma**; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA

- damage or lesions in DNA replication)
- IT Esophagus
(squamous cell **carcinoma**; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT **Carcinoma**
(squamous cell; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Lupus erythematosus
(systemic; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Bladder
(transitional cell **carcinoma**; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT Reproductive organ
(vulva, **neoplasm**; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT 154907-65-0, **Checkpoint kinase Chk1**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers)
- IT 457096-68-3P, 1-(2-Methoxy-5-nitrophenyl)-3-(pyrazin-2-yl)urea
457096-69-4P, 1-(5-Amino-2-methoxyphenyl)-3-(pyrazin-2-yl)urea
457096-71-8P, (S)-1-(2,2,2-Trifluoroethanoyl)pyrrolidine-2-carboxylic acid [4-methoxy-3-(3-(pyrazin-2-yl)ureido)phenyl]amide
457096-74-1P, 1-(2-Methoxy-4-nitrophenyl)-3-(pyrazin-2-yl)urea
457096-75-2P, 1-(4-Amino-2-methoxyphenyl)-3-(pyrazin-2-yl)urea
457096-78-5P, 3-Chloro-N-[3-methoxy-4-(3-(pyrazin-2-yl)ureido)phenyl]propionamide 457097-32-4P,
4-Methoxy-3-(3-(pyrazin-2-yl)ureido)benzoic acid 457097-53-9P,
3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzoic acid 457099-26-2P,
1-(6-Azidopyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-29-5P,
1-(5-Bromopyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-31-9P,
1-[5-(1,3-Dioxo-1,3-dihydroisoindol-2-ylmethyl)pyrazin-2-yl]-3-(2-methoxy-5-methylphenyl)urea 457099-45-5P, 1-(5-Benzoylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-67-1P, 1-(4-Aminomethyl-2-methoxyphenyl)-3-(5-methylpyrazin-2-yl)urea
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)
- IT 5424-05-5P, Quinoxalin-2-ylamine 5521-58-4P, 2-Amino-5-methylpyrazine 6294-70-8P, 2-Amino-5,6-dimethylpyrazine 6905-47-1P,
2-Amino-6-methoxypyrazine 13134-38-8P, 2-Amino-3,6-dimethylpyrazine 13535-07-4P, 2-Amino-5-ethylpyrazine 13535-13-2P, 2-Amino-5-phenylpyrazine 18591-57-6P, 2-Hydroxy-5,6-diphenylpyrazine 23145-65-5P, 3-Methoxy-4-nitrobenzyl bromide 24812-90-6P, Methyl 3-amino-4-methoxy benzoate 32111-28-7P, 2-Methylaminopyrazine

41270-66-0P, 2-Chloro-5,6-diphenylpyrazine 41270-69-3P,
 2-Amino-6-phenylpyrazine 41270-71-7P, 2-Amino-5,6-diphenylpyrazine
 53951-84-1P, Quinoline-3-carboxylic acid methyl ester 59489-71-3P,
 2-Amino-5-bromopyrazine 62992-68-1P, N-Benzylisonipecotamide
 67579-92-4P, 3-Methoxy-4-nitrobenzoyl chloride 67602-05-5P,
 2-Amino-3-bromo-5-phenylpyrazine 76849-26-8P, 2-Azido-5,6-
 diphenylpyrazine 79180-47-5P, (1,2,3,4-Tetrahydroquinolin-3-yl)methanol
 83505-98-0P, 2-Azido-3,6-dimethylpyrazine 88915-26-8P,
 4-Aminomethyl-1-benzylpiperidine 101385-90-4P, (3S)-1-Benzylpyrrolidin-3-
 ol 113305-94-5P, 2-Amino-5-cyanopyrazine 118543-98-9P,
 5-Benzoylpyrazine-2-carboxylic acid 126993-72-4P, 2-Amino-6-
 benzyloxypyrazine 174864-78-9P, 2-(4-Amino-3-methoxybenzyl)isoindole-1,3-
 dione 175393-16-5P, Quinoxaline-2-carbonyl azide 177202-62-9P,
 1,2,3,4-Tetrahydroquinoline-3-carboxylic acid methyl ester 191112-67-1P
 369638-69-7P, 369638-69-7P, (5-Bromomethylpyrazin-2-yl)carbamic acid
 tert-butyl ester 457096-83-2P, 4-Methoxy-3-((4-
 nitrophenoxycarbonyl)amino)benzoic acid methyl ester 457096-84-3P
 , 3-Methoxy-4-(3-(pyrazin-2-yl)ureido)benzoic acid methyl ester
 457097-34-6P, 4-Methoxy-3-(3-(pyrazin-2-yl)ureido)benzoic acid
 methyl ester 457097-54-0P, 3-Methoxy-4-[3-(5-methylpyrazin-2-
 yl)ureido]benzoic acid methyl ester 457097-72-2P, ((3R)-1-[(Pyridin-2-
 yl)methyl]pyrrolidin-3-yl)carbamic acid tert-butyl ester 457097-73-3P,
 (3R)-1-[(Pyridin-2-yl)methyl]pyrrolidin-3-ylamine dihydrochloride
 457097-93-7P, 4-Amino-3-trifluoromethoxybenzoic acid methyl ester
 457097-94-8P, 4-((4-Nitrophenoxycarbonyl)amino)-3-trifluoromethoxybenzoic
 acid methyl ester 457097-95-9P, 4-[3-(5-Methylpyrazin-2-
 yl)ureido]-3-trifluoromethoxybenzoic acid methyl ester
 457097-96-0P, 4-[3-(5-Methylpyrazin-2-yl)ureido]-3-
 trifluoromethoxybenzoic acid 457097-99-3P, (3S)-3-(tert-
 Butoxycarbonylamino)-1-(4-fluorobenzyl)pyrrolidine 457098-00-9P,
 (3S)-3-Amino-1-(4-fluorobenzyl)pyrrolidine 457098-02-1P,
 3-Methoxy-4-nitrobenzoic acid (3S)-1-benzylpyrrolidin-3-yl ester
 457098-03-2P, 4-Amino-3-methoxybenzoic acid (3S)-1-benzylpyrrolidin-3-yl
 ester 457098-05-4P, 3-Methoxy-4-[3-(5-trifluoromethylpyrazin-2-
 yl)ureido]benzoic acid methyl ester 457098-07-6P,
 3-Methoxy-4-[3-(5-trifluoromethylpyrazin-2-yl)ureido]benzoic acid
 457098-09-8P, 5-Methoxy-4-amino-2-trifluoromethylbenzoic acid methyl ester
 457098-10-1P, 5-Methoxy-4-((4-nitrophenoxycarbonyl)amino)-2-
 trifluoromethylbenzoic acid methyl ester 457098-11-2P,
 5-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-2-trifluoromethylbenzoic acid
 methyl ester 457098-12-3P, 5-Methoxy-4-[3-(5-methylpyrazin-2-
 yl)ureido]-2-trifluoromethylbenzoic acid 457098-14-5P,
 3-(3-Dimethylaminopropoxy)-4-nitrobenzoic acid methyl ester
 457098-15-6P, 4-Amino-3-(3-dimethylaminopropoxy)benzoic acid methyl ester
 457098-16-7P, 3-(3-Dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-
 yl)ureido]benzoic acid methyl ester 457098-18-9P, 4-Nitro-3-(pyridin-3-
 ylmethoxy)benzoic acid methyl ester 457098-19-0P, 4-Amino-3-(pyridin-3-
 ylmethoxy)benzoic acid methyl ester 457098-20-3P,
 4-[3-(5-Methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzoic acid
 methyl ester 457098-39-4P, [2-(3-Dimethylaminopropoxy)-5-
 methylphenyl]carbamic acid tert-butyl ester 457098-40-7P,
 2-(3-Dimethylaminopropoxy)-5-methylphenylamine 457098-90-7P,
 1-Ethyl-1,2,3,4-tetrahydroquinoline-3-carboxylic acid methyl ester
 457098-91-8P, [5-Methyl-2-(1,2,3,4-tetrahydroquinolin-3-
 ylmethoxy)phenyl]carbamic acid tert-butyl ester 457098-93-0P,
 (1-Ethyl-1,2,3,4-tetrahydroquinolin-3-yl)methanol 457098-94-1P,
 [2-(1-Ethyl-1,2,3,4-tetrahydroquinolin-3-ylmethoxy)-5-
 methylphenyl]carbamic acid tert-butyl ester 457098-98-5P,
 1-[2-(4-Methyl-2-nitrophenoxy)ethyl]aziridine 457099-13-7P,
 3-(4-Methyl-2-nitrophenoxy)pyridine 457099-14-8P, 5-Methyl-2-(pyridin-3-

yloxy)phenylamine 457099-16-0P, 2-(4-Methyl-2-nitrophenoxy)pyridine
 457099-17-1P, 5-Methyl-2-(pyridin-2-yloxy)phenylamine 457099-18-2P,
 3-(2-Methoxy-5-methylphenyl)-1-methyl-1-(pyrazin-2-yl)urea 457099-32-0P,
 [5-(1,3-Dioxo-1,3-dihydroisoindol-2-ylmethyl)pyrazin-2-yl]carbamic acid
 tert-butyl ester 457099-33-1P, 2-(5-Aminopyrazin-2-ylmethyl)isoindole-
 1,3-dione 457099-42-2P, 2-Amino-5-ethynylpyrazine 457099-51-3P,
 2-Methoxy-4-methoxymethyl-1-nitrobenzene 457099-52-4P,
 2-Methoxy-4-methoxymethylphenylamine 457099-55-7P, 4-Benzyloxymethyl-2-
 methoxy-1-nitrobenzene 457099-56-8P, 4-Benzyloxymethyl-2-
 methoxyphenylamine 457099-58-0P, N-Benzyl-N-(3-methoxy-4-
 nitrobenzyl)amine 457099-59-1P, Benzyl(3-methoxy-4-nitrobenzyl)carbamic
 acid tert-butyl ester 457099-61-5P, (3-Methoxy-4-
 nitrobenzyl)(methyl)carbamic acid tert-butyl ester 457099-62-6P,
 (4-Amino-3-methoxybenzyl)(methyl)carbamic acid tert-butyl ester
 457099-63-7P, N-Benzyl-N-(3-methoxy-4-nitrobenzyl)methylamine
 457099-64-8P, 4-[(Benzylmethylamino)methyl]-2-methoxyphenylamine
 457099-66-0P, (3-Methoxy-4-nitrobenzyl)dimethylamine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; prepn. of aryl and heteroaryl urea selective
Chk1 inhibitors for use as radiosensitizers and
 chemosensitizers for treating diseases and conditions related to DNA
 damage or lesions in DNA replication)

IT 196868-94-7P, N-(4-Chloro-2-methoxyphenyl)-N'-(2-pyrazinyl)urea
 457096-65-0P, 1-[2-(1,1-Difluoromethoxy)phenyl]-3-(pyrazin-2-
 yl)urea 457096-67-2P, 1-(2-Methylsulfanylphenyl)-3-(pyrazin-2-
 yl)urea 457096-70-7P, N-[4-Methoxy-3-(3-(pyrazin-2-
 yl)ureido)phenyl]succinamic acid 457096-72-9P,
 (S)-Pyrrolidine-2-carboxylic acid [4-methoxy-3-(3-(pyrazin-2-
 yl)ureido)phenyl]amide 457096-73-0P, N-[4-Methoxy-3-(3-(pyrazin-
 2-yl)ureido)phenyl]methanesulfonamide 457096-77-4P,
 C-Dimethylamino-N-[3-methoxy-4-(3-(pyrazin-2-yl)ureido)phenyl]acetamide
 trifluoroacetate 457096-79-6P, N-(4-((3-(Cyclohexyl(methyl)amino)propano
 yl)amino)-2-methoxyphenyl)-N'-(2-pyrazinyl)urea 457096-80-9P,
 3-(Cyclohexyl(methyl)amino)-N-[3-methoxy-4-(3-(pyrazin-2-
 yl)ureido)phenyl]propionamide trifluoroacetate 457096-81-0P,
 3-(Cyclopentylamino)-N-[3-methoxy-4-(3-(pyrazin-2-
 yl)ureido)phenyl]propionamide 457096-82-1P, 3-Methoxy-4-(3-
 (pyrazin-2-yl)ureido)benzoic acid 457096-85-4P,
 N-Butyl-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide 457096-86-5P
 , 1-[4-[(Benzylmethylamino)methyl]-2-methoxyphenyl]-3-(5-methylpyrazin-2-
 yl)urea 457096-87-6P, N-Benzyl-3-methoxy-4-(3-(pyrazin-2-
 yl)ureido)benzamide 457096-89-8P, 3-Methoxy-N-phenethyl-4-(3-
 (pyrazin-2-yl)ureido)benzamide 457096-90-1P,
 3-Methoxy-N-(3-phenylpropyl)-4-(3-(pyrazin-2-yl)ureido)benzamide
 457096-92-3P, N-(2-(Benzenesulfonyl)ethyl)-3-methoxy-4-(3-(pyrazin-
 2-yl)ureido)benzamide 457096-95-6P, N-(4-Iodobenzyl)-3-methoxy-4-
 (3-(pyrazin-2-yl)ureido)benzamide 457096-97-8P 457096-99-0P,
 3-Methoxy-4-(3-(pyrazin-2-yl)ureido)-N-(2-(pyridin-4-yl)ethyl)benzamide
 457097-01-7P, N-(1H-Benzimidazol-2-ylmethyl)-3-methoxy-4-(3-
 (pyrazin-2-yl)ureido)benzamide 457097-04-0P 457097-05-1P
 , 3-Methoxy-N-[3-(methylphenylamino)propyl]-4-(3-(pyrazin-2-
 yl)ureido)benzamide 457097-08-4P 457097-10-8P, N-((3R)-1-
 Benzylpyrrolidin-3-yl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide
 457097-13-1P, N-((3S)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-(3-(pyrazin-2-
 yl)ureido)benzamide 457097-16-4P, N-(2-Dimethylaminoethyl)-3-
 methoxy-N-methyl-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-18-6P
 , 3-Methoxy-N-(3-methylaminopropyl)-4-(3-(pyrazin-2-yl)ureido)benzamide
 457097-21-1P, N-(3-Dimethylaminopropyl)-3-methoxy-4-(3-(pyrazin-2-
 yl)ureido)benzamide 457097-23-3P, N-(3-Dimethylaminopropyl)-3-

methoxy-N-methyl-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-25-5P
 , 3-Methoxy-N-(3-(morpholin-4-yl)propyl)-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-27-7P, 3-Methoxy-N-[3-(4-methylpiperazin-1-yl)propyl]-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-29-9P, [2-[3-Methoxy-4-(3-(pyrazin-2-yl)ureido)benzoylamino]ethyl]trimethylammonium chloride 457097-35-7P, N-Butyl-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-36-8P, N-Benzyl-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-37-9P, 4-Methoxy-N-phenethyl-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-38-0P, 4-Methoxy-N-(3-phenylpropyl)-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-39-1P, N-(2-(Benzenesulfonyl)ethyl)-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-40-4P, 4-Methoxy-3-(3-(pyrazin-2-yl)ureido)-N-(2-(pyridin-2-yl)ethyl)benzamide 457097-41-5P, 4-Methoxy-3-(3-(pyrazin-2-yl)ureido)-N-(2-(pyridin-4-yl)ethyl)benzamide 457097-42-6P, N-(1H-Benzimidazol-2-ylmethyl)-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-43-7P, N-(2-(1H-Indol-3-yl)ethyl)-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-44-8P, 4-Methoxy-N-[3-(methylphenylamino)propyl]-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-45-9P 457097-46-0P, N-(2-Dimethylaminoethyl)-4-methoxy-N-methyl-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-47-1P, 4-Methoxy-N-(3-methylaminopropyl)-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-48-2P, N-(3-Dimethylaminopropyl)-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-49-3P, N-(3-Dimethylaminopropyl)-4-methoxy-N-methyl-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-50-6P, 4-Methoxy-N-[3-(4-methylpiperazin-1-yl)propyl]-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-51-7P, [2-[4-Methoxy-3-(3-(pyrazin-2-yl)ureido)benzoylamino]ethyl]trimethylammonium chloride 457097-52-8P, 4-Methoxy-N-(3-(morpholin-4-yl)propyl)-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-57-3P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-(2-(pyridin-2-yl)ethyl)benzamide 457097-59-5P, N-(1-Benzylpiperidin-4-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-61-9P, N-(3-Dimethylaminopropyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-63-1P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-(3-(morpholin-4-yl)propyl)benzamide 457097-65-3P, N-(2-(Dimethylamino)-2-phenylethyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-68-6P, N-(2-(Dimethylamino)-1-phenylethyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-70-0P, N-(1-Azabicyclo[2.2.2]oct-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-71-1P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3R)-1-(pyridin-2-yl)methylpyrrolidin-3-yl)benzamide 457097-74-4P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3R)-1-methylpyrrolidin-3-yl)benzamide 457097-76-6P, N-((3R)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-77-7P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3R)-1-[(pyridin-4-yl)methyl]pyrrolidin-3-yl)benzamide 457097-79-9P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3S)-1-[(thiophen-2-yl)methyl]pyrrolidin-3-yl)benzamide 457097-81-3P, N-((3R)-1-Cyclohexylmethylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-83-5P, N-((3S)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-84-6P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3S)-1-[(pyridin-2-yl)methyl]pyrrolidin-3-yl)benzamide 457097-86-8P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3S)-1-[(pyridin-3-yl)methyl]pyrrolidin-3-yl)benzamide 457097-87-9P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3S)-1-[(pyridin-4-yl)methyl]pyrrolidin-3-yl)benzamide 457097-90-4P, N-((3S)-1-Cyclohexylmethylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-

2-yl)ureido]benzamide 457097-92-6P, N-((3S)-1-Benzylpyrrolidin-3-yl)-4-[3-(5-methylpyrazin-2-yl)ureido]-3-trifluoromethoxybenzamide
457097-97-1P, N-(1-Benzylpiperidin-4-ylmethyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-98-2P, N-[(3S)-1-(4-Fluorobenzyl)pyrrolidin-3-yl]-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457098-01-0P**, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzoic acid (3S)-1-benzylpyrrolidin-3-yl ester 457098-04-3P, N-((3S)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-trifluoromethylpyrazin-2-yl)ureido]benzamide **457098-08-7P**, 5-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-(2-(pyridin-2-yl)ethyl)-2-trifluoromethylbenzamide **457098-13-4P**, 3-(3-Dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]benzoic acid **457098-17-8P**, 4-[3-(5-Methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzoic acid **457098-21-4P**, 3-(3-Dimethylaminopropoxy)-4-[3-(5-n-methylpyrazin-2-yl)ureido]benzamide **457098-22-5P**, 3-(3-Dimethylaminopropoxy)-N,N-dimethyl-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457098-23-6P**, N-Benzyl-3-(3-dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457098-24-7P**, N-Benzyl-3-(3-dimethylaminopropoxy)-N-methyl-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457098-25-8P**, 3-(3-Dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]-N-(2-(morpholin-4-yl)ethyl)benzamide **457098-26-9P**, 3-(3-Dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]-N-[2-(1-methylpyrrolidin-2-yl)ethyl]benzamide **457098-27-0P**, N-(2-Dimethylaminoethyl)-3-(3-dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457098-28-1P, N-((3S)-1-Benzylpyrrolidin-3-yl)-3-(3-dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457098-29-2P**, 4-[3-(5-Methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide **457098-30-5P**, N-Methyl-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide **457098-31-6P**, N-Dimethyl-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide **457098-32-7P**, N-Benzyl-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide **457098-33-8P**, N-Benzyl-N-methyl-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide **457098-34-9P**, 4-[3-(5-Methylpyrazin-2-yl)ureido]-N-(2-(morpholin-4-yl)ethyl)-3-(pyridin-3-ylmethoxy)benzamide **457098-35-0P**, 4-[3-(5-Methylpyrazin-2-yl)ureido]-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-3-(pyridin-3-ylmethoxy)benzamide **457098-36-1P**, N-(2-Dimethylaminoethyl)-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide 457098-37-2P 457098-38-3P, 1-[2-(3-Dimethylaminopropoxy)-5-methylphenyl]-3-(pyrazin-2-yl)urea 457098-41-8P, 1-[2-(2-Dimethylaminoethoxy)-5-methylphenyl]-3-(pyrazin-2-yl)urea 457098-42-9P, 1-[5-Methyl-2-(pyridin-3-ylmethoxy)phenyl]-3-(pyrazin-2-yl)urea 457098-43-0P, 1-[5-Methyl-2-[3-(2-oxopyrrolidin-1-yl)propoxy]phenyl]-3-(pyrazin-2-yl)urea 457098-44-1P, 1-[5-Methyl-2-(2-(morpholin-4-yl)ethoxy)phenyl]-3-(pyrazin-2-yl)urea 457098-45-2P, 1-[5-Methyl-2-(3-(morpholin-4-yl)propoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-46-3P, 1-[2-(3-Dimethylaminopropoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-47-4P, 1-[5-Methyl-2-(2-(morpholin-4-yl)ethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-48-5P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-2-ylmethoxy)phenyl]urea 457098-49-6P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-4-ylmethoxy)phenyl]urea 457098-50-9P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-3-ylmethoxy)phenyl]urea 457098-51-0P, 1-[2-(2-Dimethylaminoethoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea **457098-52-1P**, 1-(5-Methylpyrazin-2-yl)-3-[2-(pyridin-3-ylmethoxy)-5-trifluoromethylphenyl]urea 457098-53-2P, 1-[5-Methyl-2-(6-methylpyridin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-55-4P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(2-(pyridin-2-yl)ethoxy)phenyl]urea 457098-57-6P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-

2-(3-(pyridin-2-yl)propoxy)phenyl]urea 457098-59-8P,
 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(3-(pyridin-4-yl)propoxy)phenyl]urea 457098-60-1P, 1-[2-[2-(Benzylmethylamino)ethoxy]-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-62-3P,
 1-[5-Methyl-2-(1-methylpiperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-64-5P, 1-[2-[2-(4-Dimethylaminophenyl)ethoxy]-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-66-7P,
 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(3-(pyridin-3-yl)propoxy)phenyl]urea 457098-68-9P, 1-[2-(2-(Dimethylamino)-1-(dimethylamino)methyl)ethoxy]-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-70-3P, 1-[5-Methyl-2-((2S)-1-methylpyrrolidin-2-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-72-5P,
 1-[2-((2S)-1-Benzylpyrrolidin-2-ylmethoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-74-7P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(2-pyrrolidin-1-ylethoxy)phenyl]urea 457098-75-8P,
 1-[5-Methyl-2-[2-(1-methylpyrrolidin-2-yl)ethoxy]phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-76-9P, 1-[2-(3H-Imidazol-4-ylmethoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-77-0P,
 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(2-(pyridin-3-yl)ethoxy)phenyl]urea 457098-78-1P, 1-[5-Methyl-2-(3-(piperidin-1-yl)propoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-79-2P, 1-[5-Methyl-2-(1-methylpiperidin-4-yloxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-80-5P,
 1-[2-(1-Benzylpiperidin-4-yloxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-81-6P, 1-[5-Methyl-2-((3S)-1-methylpiperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-82-7P,
 1-[5-Methyl-2-((3R)-1-methylpiperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-84-9P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(1-(pyridin-3-yl)ethoxy)phenyl]urea 457098-85-0P,
 1-[5-Methyl-2-(1-methylpiperidin-2-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-86-1P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(tetrahydrofuran-2-ylmethoxy)phenyl]urea 457098-87-2P,
 1-[5-Methyl-2-(1-methylpiperidin-4-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-88-3P, 1-[5-Methyl-2-(1-methylpiperidin-3-yloxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457098-89-4P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(1,2,3,4-tetrahydroquinolin-3-ylmethoxy)phenyl]urea 457098-92-9P, 1-[2-(1-Ethyl-1,2,3,4-tetrahydroquinolin-3-ylmethoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457098-95-2P,
 1-[5-Methyl-2-(1-methylpiperidin-3-ylmethoxy)phenyl]-3-(quinoxalin-2-yl)urea 457098-96-3P, 1-[5-Methyl-2-(pyridin-3-ylmethoxy)phenyl]-3-(quinoxalin-2-yl)urea 457098-99-6P, 1-[2-(2-(Aziridin-1-yl)ethoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457099-00-2P,
 1-[2-(3-Dimethylaminobenzyloxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457099-01-3P, 1-[2-(1-Isopropylpyrrolidin-3-yloxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea 457099-02-4P,
 1-[5-Methyl-2-(1-methylpyrrolidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-03-5P, 1-[5-Methyl-2-(piperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-04-6P, 1-[5-Fluoro-2-(pyridin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-05-7P,
 1-[5-Fluoro-2-(1-methylpiperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-06-8P, 1-[5-Fluoro-2-(1-methylpiperidin-4-yloxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-07-9P,
 1-[4-Fluoro-2-(pyridin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-08-0P, 1-[4-Fluoro-2-(1-methylpiperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-09-1P, 1-[4-Fluoro-2-(1-methylpiperidin-4-yloxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-10-4P, 1-[3,4-Difluoro-2-(pyridin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-11-5P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-4-yloxy)phenyl]urea 457099-12-6P, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-3-yloxy)phenyl]urea 457099-15-9P,
 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-2-yloxy)phenyl]urea

457099-19-3P 457099-21-7P, 1-(5,6-Dimethylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-22-8P, 1-(2-Methoxy-5-methylphenyl)-3-(5-trifluoromethylpyrazin-2-yl)urea 457099-23-9P, 1-(5,6-Diphenylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-24-0P, 1-[3-Benzyl-5-(4-methoxyphenyl)pyrazin-2-yl]-3-(2-methoxy-5-methylphenyl)urea
 457099-27-3P, 1-(6-Aminopyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea
 457099-28-4P, 1-(6-Chloropyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea
 457099-30-8P, 1-(3,5-Dibromopyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea
 457099-34-2P, 1-(5-Aminomethylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-35-3P, 1-(2-Methoxy-5-methylphenyl)-3-(6-methoxypyrazin-2-yl)urea 457099-37-5P, 1-(6-Benzyloxypyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-40-0P, 1-(2-Methoxy-5-methylphenyl)-3-(5-methoxypyrazin-2-yl)urea 457099-41-1P, 1-(5-Ethynylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-43-3P, 1-(5-Ethylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-44-4P, 1-(5-Cyanopyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-46-6P, 1-[5-(Hydroxyphenylmethyl)pyrazin-2-yl]-3-(2-methoxy-5-methylphenyl)urea
 457099-47-7P, 1-(3-Bromo-5-phenylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea 457099-48-8P, 1-(2-Methoxy-5-methylphenyl)-3-(5-phenylpyrazin-2-yl)urea 457099-49-9P 457099-50-2P, 1-(3,6-Dimethylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea
 457099-53-5P, 1-(2-Methoxy-4-methoxymethylphenyl)-3-(5-methylpyrazin-2-yl)urea 457099-54-6P, 1-(4-Benzyloxymethyl-2-methoxyphenyl)-3-(5-methylpyrazin-2-yl)urea 457099-57-9P, 1-[4-[(Benzylamino)methyl]-2-methoxyphenyl]-3-(5-methylpyrazin-2-yl)urea
 457099-60-4P, 1-(2-Methoxy-4-[(methylamino)methyl]phenyl)-3-(5-methylpyrazin-2-yl)urea 457099-65-9P, 1-(4-[(Dimethylamino)methyl]-2-methoxyphenyl)-3-(5-methylpyrazin-2-yl)urea
 457099-68-2P, 1-[2-Methoxy-4-[(thiophen-2-ylmethyl)amino]methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea
 457099-69-3P, 1-[2-Methoxy-4-[(thiophen-3-ylmethyl)amino]methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea
 457099-70-6P, 1-[4-[(Furan-2-ylmethyl)amino]methyl]-2-methoxyphenyl]-3-(5-methylpyrazin-2-yl)urea 457099-71-7P, 1-[4-[(Furan-3-ylmethyl)amino]methyl]-2-methoxyphenyl]-3-(5-methylpyrazin-2-yl)urea 457099-72-8P, 1-[2-Methoxy-4-[(2-methoxybenzylamino)methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea
 457099-73-9P, 1-[2-Methoxy-4-[(3-methoxybenzylamino)methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-74-0P, 1-[2-Methoxy-4-[(4-methoxybenzylamino)methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea
 457099-75-1P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]acetamide 457099-76-2P, 2-Methoxy-N-[3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]acetamide 457099-77-3P, 2-(Dimethylamino)-N-[3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]acetamide 457099-78-4P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]-2-(pyridin-2-yl)acetamide
 457099-79-5P
 , N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]-2-(4-methoxyphenyl)acetamide 457099-80-8P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]benzamide 457099-81-9P, Pyridine-2-carboxylic acid 3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzylamide 457099-82-0P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]nicotinamide 457099-83-1P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]isonicotinamide
 457099-84-2P, Thiophene-2-carboxylic acid 3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzylamide 457099-85-3P, 3-(Dimethylamino)-N-[3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]benzamide 457099-86-4P 457099-87-5P
 457099-88-6P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]benzenesulfonamide 457099-89-7P,

N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]-2-trifluoromethoxybenzenesulfonamide 457099-90-0P,
 3-Methoxy-N-[3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]benzenesulfonamide 457099-91-1P,
 4-Methoxy-N-[3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]benzenesulfonamide 457099-92-2P,
 Pyridine-2-sulfonic acid 3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzylamide 457099-93-3P, N-(2-Methoxy-3-((2-(4-morpholinyl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea 457099-94-4P, N-(2-Methoxy-3-((2-(1-methylpyrrolidin-2-yl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea 457099-95-5P,
 N-(4-((2-Chloroethyl)carbamoyl)-2-methoxyphenyl)-N'-(2-pyrazinyl)urea 457099-96-6P, N-(2-Methoxy-4-((2-(4-morpholinyl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea 457099-97-7P, N-(2-Methoxy-4-((2-(1-methylpyrrolidin-2-yl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea 457099-98-8P, N-(2-Methoxy-4-((2-((methylsulfonyl)amino)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea 457099-99-9P,
 N-(3-(Ethyl(methyl)carbamoyl)-2-methoxyphenyl)-N'-(2-pyrazinyl)urea 457100-00-4P, N-(2-Methoxy-5-methylphenyl)-N'-(4-pyrimidinyl)urea 457100-01-5P, N-(2-Methoxy-5-methylphenyl)-N'-(1,2,4-triazin-3-yl)urea 457100-02-6P, N-(2-Methoxy-5-methylphenyl)-N'-(6-phenyl-2-pyrazinyl)urea 457100-03-7P, N-(2-Methoxy-5-methylphenyl)-N'-(2-pyrazinyl)urea 457100-04-8P, N-(4-((3-(Dimethylamino)propanoyl)amino)-2-methoxyphenyl)-N'-(2-pyrazinyl)urea 458523-51-8P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3R)-1-((thiophen-2-yl)methyl)pyrrolidin-3-yl)benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryl and heteroaryl urea selective Chk1 inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)

IT 61-54-1, Tryptamine 64-04-0, Phenethylamine 85-41-6, Phthalimide 89-60-1, 1-Chloro-4-methyl-2-nitrobenzene 95-84-1, 2-Amino-4-methylphenol 98-01-1, Furfural, reactions 98-03-3, Thiophene-2-carboxaldehyde 98-09-9, Benzenesulfonyl chloride 98-68-0, 4-Methoxybenzenesulfonyl chloride 98-80-6, Phenylboronic acid 98-97-5, 2-Pyrazinecarboxylic acid 100-39-0, Benzyl bromide 100-46-9, Benzylamine, reactions 100-51-6, Benzyl alcohol, reactions 100-52-7, Benzaldehyde, reactions 100-55-0, 3-Pyridylcarbinol 100-60-7, N-Cyclohexylmethylamine 101-98-4, N-Methyl-N-benzylethanolamine 103-67-3, N-Methylbenzylamine 103-74-2, 2-(2-Pyridyl)ethanol 104-58-5, 3-(Piperidin-1-yl)propan-1-ol 106-52-5, 1-Methylpiperidin-4-ol 108-00-9, 2-Dimethylaminoethylamine 108-01-0, N,N-Dimethylethanolamine 108-30-5, Succinic anhydride, reactions 109-00-2, Pyridin-3-ol 109-55-7, N,N-Dimethyl-1,3-propanediamine 119-33-5, 2-Nitro-4-methylphenol 123-00-2, 3-(Morpholin-4-yl)propylamine 123-11-5, 4-Methoxybenzaldehyde, reactions 134-81-6, Benzil 135-02-4, 2-Methoxybenzaldehyde 142-08-5, Pyridin-2-ol 142-25-6, N,N,N'-Trimethylethane-1,2-diamine 364-74-9, 1,4-Difluoro-2-nitrobenzene 431-03-8, Butanedione 446-36-6, 2-Nitro-5-fluorophenol 454-81-9, 2-Hydroxy-5-trifluoromethylaniline 459-46-1, 4-Fluorobenzyl bromide 498-60-2, Furan-3-carboxaldehyde 498-62-4, Thiophene-3-carboxaldehyde 500-22-1, Pyridine-3-carboxaldehyde 501-53-1, Benzyl chloroformate 586-95-8, 4-Hydroxymethylpyridine 586-98-1, 2-Hydroxymethylpyridine 591-31-1, 3-Methoxybenzaldehyde 622-40-2, 2-(Morpholin-4-yl)ethanol 625-36-5, 3-Chloropropanoyl chloride 626-61-9, 4-Chloropyridine 654-99-9, 3-Fluoro-6-trifluoromethylbenzoic acid 713-52-0, 3-Hydroxy-4-nitrobenzoic acid methyl ester 822-55-9, (3H-Imidazol-4-yl)methanol 879-65-2, Quinoxaline-2-carboxylic acid 1003-03-8, Cyclopentylamine 1072-52-2, 2-(Aziridin-1-yl)ethanol

1118-68-9, N,N-Dimethylglycine 1121-60-4, Pyridine-2-carboxaldehyde
 1448-87-9, 2-Chloroquinoxaline 1668-10-6, Glycinamide hydrochloride
 2038-03-1, 2-(Morpholin-4-yl)ethylamine 2038-57-5, Phenpropylamine
 2486-69-3, 4-Amino-3-methoxybenzoic acid 2629-72-3, 3-(4-Pyridyl)propanol
 2706-56-1, 2-(Pyridin-2-yl)ethylamine 2859-67-8, 3-(3-Pyridyl)propanol
 2859-68-9, 3-(2-Pyridyl)propanol 2955-88-6, 2-(Pyrrolidin-1-yl)ethanol
 3179-63-3, 3-(Dimethylamino)propanol 3222-47-7, 6-Methylnicotinic acid
 4441-30-9, 3-(Morpholin-4-yl)propanol 4543-96-8, N,N,N'-Trimethyl-1,3-propanediamine
 4572-03-6, 3-(4-Methylpiperazin-1-yl)propylamine 4606-65-9, 3-Hydroxymethylpiperidine
 4693-91-8, 2-(4-Methoxyphenyl)acetyl chloride 4727-72-4, 1-Benzylpiperidin-4-ol
 5021-33-0, (1-Methylpyrrolidin-3-yl)methanol 5049-61-6, Aminopyrazine
 5081-36-7, 3-Methoxy-4-nitrobenzoic acid 5271-67-0, Thiophene-2-carbonyl chloride
 5521-55-1, 5-Methylpyrazine-2-carboxylic acid 5805-57-2, C-(1H-Benzimidazol-2-yl)methylamine
 5966-51-8, 1,3-Bis(dimethylamino)propan-2-ol 6238-14-8, 1-Azabicyclo[2.2.2]oct-3-ylamine
 6291-84-5, N1-Methylpropane-1,3-diamine 6293-56-7, 2-(Pyridin-3-yl)ethanol
 6342-21-8, N-(2-Dimethylamino-2-phenylethyl)amine 6480-68-8, Quinoline-3-carboxylic acid
 7583-53-1, 3-Hydroxymethyl-1-methylpiperidine 7693-46-1, 4-Nitrophenyl chloroformate
 10130-74-2, 3-Methoxybenzenesulfonyl chloride 10400-19-8, Nicotinoyl chloride
 13258-63-4, 2-(Pyridin-4-yl)ethylamine 14254-57-0, Isonicotinoyl chloride
 14508-49-7, 2-Chloropyrazine 16629-19-9, Thiophene-2-sulfonyl chloride
 18471-40-4, 3-Amino-1-benzylpyrrolidine 23501-93-1, (3-Dimethylaminophenyl)methanol
 24241-18-7, 2-Amino-3,5-dibromopyrazine 29745-44-6, Pyridine-2-carbonyl chloride
 31788-88-2, N-(2-Dimethylamino-1-phenylethyl)amine 33332-28-4, 2-Amino-6-chloropyrazine
 33484-67-2, 2-Methoxy-4-nitrophenyl isocyanate 34381-71-0, (2S)-1-Methylpyrrolidin-2-ylmethanol
 36724-68-2, N-Trifluoroacetyl-(S)-prolyl chloride 37689-86-4, p-Nitrophenyl carbamate
 38170-37-5, 2-N,N,N-Trimethylammonium ethylamine 38557-72-1, 2-Chloro-3,5-dimethylpyrazine
 38870-89-2, Methoxyacetyl chloride 39546-32-2, Isonipecotamide 39959-59-6, 4-Iodobenzylamine
 42729-56-6, 3-Hydroxy-1-isopropylpyrrolidine 50438-75-0, 2-(4-Dimethylaminophenyl)ethanol
 50541-93-0, 4-Amino-1-benzylpiperidine 51387-90-7, [2-(1-Methylpyrrolidin-2-yl)ethyl]amine
 51552-16-0, Dimethylaminoacetyl chloride 52260-30-7, 2-(Methylthio)phenyl isocyanate
 53485-07-7, N1-Methyl-N1-phenylpropane-1,3-diamine 53912-80-4, (2S)-1-Benzylpyrrolidin-2-ylmethanol
 54263-82-0, 3-(Dimethylamino)benzoyl chloride 59741-04-7, 2-Methoxy-5-methylphenyl isocyanate
 59741-17-2, 2-Methoxy-5-nitrophenyl isocyanate 62012-15-1, 3-(2-Oxopyrrolidin-1-yl)propanol
 66715-65-9, Pyridine-2-sulfonyl chloride 67004-64-2, 2-(1-Methylpyrrolidin-2-yl)ethanol
 67215-15-0 68947-43-3, 1-Methylpiperidine-4-carboxylic acid 69816-37-1
 69816-38-2, 5-Trifluoromethyl-2-aminopyrazine 80866-88-2, 3-Methoxy-4-nitrobenzyl alcohol
 82419-26-9, 2,3-Difluoro-6-nitrophenol 88495-54-9, (S)-(+)-N-Boc-nipecotic acid
 100243-39-8, (3S)-3-Hydroxypyrrolidine 103008-51-1, 2-Trifluoromethoxybenzenesulfonyl chloride
 114715-38-7 114715-39-8, (3R)-Amino-1-benzylpyrrolidine 122536-76-9 131852-54-5
 144659-13-2, 2-(2-Pyridyl)acetyl chloride 147081-49-0, (R)-N-Boc-3-aminopyrrolidine
 163438-09-3 175137-14-1, 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carbonyl chloride 175278-22-5,
 4-Amino-3-trifluoromethoxybenzoic acid 186589-03-7, 2-(Difluoromethoxy)phenyl isocyanate
 256526-96-2, [(3S)-1-[(Pyridin-3-yl)methyl]pyrrolidin-3-yl]amine 457097-55-1, 3-Methoxy-4-((4-nitrophenoxycarbonyl)amino)benzoic acid methyl ester
 457097-75-5 457097-78-8, (1R)-[(Pyridin-4-yl)methyl]pyrrolidin-3-ylamine 457097-80-2, [(3R)-1-[(Thiophen-2-yl)methyl]pyrrolidin-3-yl]amine
 457097-82-4, (3R)-1-Cyclohexylmethylpyrrolidin-3-ylamine 457097-85-7 457097-88-0, [(3S)-1-[(Pyridin-4-yl)methyl]pyrrolidin-3-yl]amine

457097-89-1, [(3S)-1-[(Thiophen-2-yl)methyl]pyrrolidin-3-yl]amine
 457097-91-5, [(3S)-1-(Cyclohexylmethyl)pyrrolidin-3-yl]amine
 457098-06-5, 4-Methoxy-3-((4-nitrophenylcarbonyl)amino)benzoic acid methyl ester
 457098-54-3, 5-Methyl-2-(6-methylpyridin-3-ylmethoxy)phenylamine
 457098-56-5, 5-Methyl-2-(2-(pyridin-2-yl)ethoxy)phenylamine 457098-58-7
 457098-61-2, 2-[2-(Benzylmethylamino)ethoxy]-5-methylphenylamine
 457098-63-4, 5-Methyl-2-(1-methylpiperidin-3-ylmethoxy)phenylamine
 457098-65-6, 2-[2-(4-Dimethylaminophenyl)ethoxy]-5-methylphenylamine
 457098-67-8, 5-Methyl-2-(3-(pyridin-3-yl)propoxy)phenylamine
 457098-69-0, 2-(2-Amino-4-methylphenoxy)-N,N,N',N'-tetramethylpropane-1,3-diamine
 457098-71-4, 5-Methyl-2-((2S)-1-methylpyrrolidin-2-ylmethoxy)phenylamine
 457098-73-6, 5-Methyl-2-((2S)-1-benzylpyrrolidin-2-ylmethoxy)phenylamine
 457098-83-8, 5-Methylpyrazine-2-carboxylic acid azide
 457098-97-4, 5-Methyl-2-(pyridin-3-ylmethoxy)phenylamine
 457099-20-6, 2-Amino-4-methylpyrazine 457099-25-1, 2-Amino-3-benzyl-4-(4-methoxyphenyl)pyrazine

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)


IT 457096-68-3P, 1-(2-Methoxy-5-nitrophenyl)-3-(pyrazin-2-yl)urea
 457096-69-4P, 1-(5-Amino-2-methoxyphenyl)-3-(pyrazin-2-yl)urea
 457096-71-8P, (S)-1-(2,2,2-Trifluoroethanoyl)pyrrolidine-2-carboxylic acid [4-methoxy-3-(3-(pyrazin-2-yl)ureido)phenyl]amide
 457096-74-1P, 1-(2-Methoxy-4-nitrophenyl)-3-(pyrazin-2-yl)urea
 457096-75-2P, 1-(4-Amino-2-methoxyphenyl)-3-(pyrazin-2-yl)urea
 457096-78-5P, 3-Chloro-N-[3-methoxy-4-(3-(pyrazin-2-yl)ureido)phenyl]propionamide 457097-32-4P, 4-Methoxy-3-(3-(pyrazin-2-yl)ureido)benzoic acid 457097-53-9P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzoic acid
 457099-67-1P, 1-(4-Aminomethyl-2-methoxyphenyl)-3-(5-methylpyrazin-2-yl)urea

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(intermediate; prepn. of aryl and heteroaryl urea selective **Chk1** inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)


RN 457096-68-3 HCAPLUS

CN Urea, N-(2-methoxy-5-nitrophenyl)-N'-pyrazinyl- (9CI) (CA INDEX NAME)



RN 457096-69-4 HCAPLUS


CN Urea, N-(5-amino-2-methoxyphenyl)-N'-pyrazinyl- (9CI) (CA INDEX NAME)



RN 457096-71-8 HCAPLUS


CN 2-Pyrrolidinecarboxamide, N-[4-methoxy-3-[(pyrazinylamino)carbonyl]amino]phenyl]-1-(trifluoroacetyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 457096-74-1 HCAPLUS

CN Urea, N-(2-methoxy-4-nitrophenyl)-N'-pyrazinyl- (9CI) (CA INDEX NAME)




RN 457096-75-2 HCAPLUS

CN Urea, N-(4-amino-2-methoxyphenyl)-N'-pyrazinyl- (9CI) (CA INDEX NAME)




RN 457096-78-5 HCAPLUS


CN Propanamide, 3-chloro-N-[3-methoxy-4-[(pyrazinylamino)carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 457097-32-4 HCAPLUS
 CN Benzoic acid, 4-methoxy-3-[[(pyrazinylamino) carbonyl] amino] - (9CI) (CA INDEX NAME)



RN 457097-53-9 HCAPLUS
 CN Benzoic acid, 3-methoxy-4-[[[(5-methylpyrazinyl) amino] carbonyl] amino] - (9CI) (CA INDEX NAME)



RN 457099-67-1 HCAPLUS
 CN Urea, N-[4-(aminomethyl)-2-methoxyphenyl]-N'-(5-methylpyrazinyl) - (9CI) (CA INDEX NAME)



IT 457096-84-3P, 3-Methoxy-4-(3-(pyrazin-2-yl)ureido)benzoic acid methyl ester 457097-34-6P, 4-Methoxy-3-(3-(pyrazin-2-yl)ureido)benzoic acid methyl ester 457097-54-0P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzoic acid methyl ester 457097-95-9P, 4-[3-(5-Methylpyrazin-2-yl)ureido]-3-trifluoromethoxybenzoic acid methyl ester 457097-96-0P, 4-[3-(5-Methylpyrazin-2-yl)ureido]-3-trifluoromethoxybenzoic acid 457098-05-4P, 3-Methoxy-4-[3-(5-trifluoromethylpyrazin-2-

yl)ureido]benzoic acid methyl ester **457098-07-6P**,
 3-Methoxy-4-[3-(5-trifluoromethylpyrazin-2-yl)ureido]benzoic acid
457098-11-2P, 5-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-2-
 trifluoromethylbenzoic acid methyl ester **457098-12-3P**,
 5-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-2-trifluoromethylbenzoic acid
457098-16-7P, 3-(3-Dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-
 yl)ureido]benzoic acid methyl ester **457098-20-3P**,
 4-[3-(5-Methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzoic acid
 methyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)


(intermediate; prepn. of aryl and heteroaryl urea selective

Chk1 inhibitors for use as radiosensitizers and

chemosensitizers for treating diseases and conditions related to DNA
 damage or lesions in DNA replication)


RN 457096-84-3 HCAPLUS

CN Benzoic acid, 3-methoxy-4-[[pyrazinylamino]carbonyl]amino]-, methyl ester
 (9CI) (CA INDEX NAME)




RN 457097-34-6 HCAPLUS

CN Benzoic acid, 4-methoxy-3-[[pyrazinylamino]carbonyl]amino]-, methyl ester
 (9CI) (CA INDEX NAME)




RN 457097-54-0 HCAPLUS


CN Benzoic acid, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-,
 methyl ester (9CI) (CA INDEX NAME)




RN 457097-95-9 HCAPLUS
 CN Benzoic acid, 4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-3-(trifluoromethoxy)-, methyl ester (9CI) (CA INDEX NAME)




RN 457097-96-0 HCAPLUS
 CN Benzoic acid, 4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 457098-05-4 HCAPLUS
 CN Benzoic acid, 3-methoxy-4-[[[5-(trifluoromethyl)pyrazinyl]amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 457098-07-6 HCAPLUS
 CN Benzoic acid, 3-methoxy-4-[[[5-(trifluoromethyl)pyrazinyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457098-11-2 HCAPLUS

CN Benzoic acid, 5-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-2-(trifluoromethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 457098-12-3 HCAPLUS

CN Benzoic acid, 5-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 457098-16-7 HCAPLUS

CN Benzoic acid, 3-[3-(dimethylamino)propoxy]-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 457098-20-3 HCAPLUS

CN Benzoic acid, 4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-3-(3-pyridinylmethoxy)-, methyl ester (9CI) (CA INDEX NAME)



IT 196868-94-7P, N-(4-Chloro-2-methoxyphenyl)-N'-(2-pyrazinyl)urea
 457096-65-0P, 1-[2-(1,1-Difluoromethoxy)phenyl]-3-(pyrazin-2-yl)urea
 457096-67-2P, 1-(2-Methylsulfanylphenyl)-3-(pyrazin-2-yl)urea
 457096-70-7P, N-[4-Methoxy-3-(3-(pyrazin-2-yl)ureido)phenyl]succinamic acid
 457096-72-9P, (S)-Pyrrolidine-2-carboxylic acid [4-methoxy-3-(3-(pyrazin-2-yl)ureido)phenyl]amide
 457096-73-0P, N-[4-Methoxy-3-(3-(pyrazin-2-yl)ureido)phenyl]methanesulfonamide
 457096-77-4P, C-Dimethylamino-N-[3-methoxy-4-(3-(pyrazin-2-yl)ureido)phenyl]acetamide
 trifluoroacetate 457096-82-1P, 3-Methoxy-4-(3-(pyrazin-2-yl)ureido)benzoic acid
 457096-85-4P, N-Butyl-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide
 457096-86-5P, 1-[4-[(Benzylmethylamino)methyl]-2-methoxyphenyl]-3-(5-methylpyrazin-2-yl)urea
 457096-87-6P, N-Benzyl-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide
 457096-89-8P, 3-Methoxy-N-phenethyl-4-(3-(pyrazin-2-yl)ureido)benzamide
 457096-90-1P, 3-Methoxy-N-(3-phenylpropyl)-4-(3-(pyrazin-2-yl)ureido)benzamide
 457096-92-3P, N-(2-(Benzenesulfonyl)ethyl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide
 457096-95-6P, N-(4-Iodobenzyl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide
 457097-01-7P, N-(1H-Benzimidazol-2-ylmethyl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide
 457097-04-0P 457097-05-1P, 3-Methoxy-N-[3-(methylphenylamino)propyl]-4-(3-(pyrazin-2-yl)ureido)benzamide
 457097-16-4P, N-(2-Dimethylaminoethyl)-3-methoxy-N-methyl-4-(3-(pyrazin-2-yl)ureido)benzamide
 457097-18-6P, 3-Methoxy-N-(3-methylaminopropyl)-4-(3-(pyrazin-2-yl)ureido)benzamide
 457097-21-1P, N-(3-Dimethylaminopropyl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide
 457097-23-3P, N-(3-Dimethylaminopropyl)-3-methoxy-N-methyl-4-(3-(pyrazin-2-yl)ureido)benzamide
 457097-25-5P, 3-Methoxy-N-(3-(morpholin-4-yl)propyl)-4-(3-(pyrazin-2-yl)ureido)benzamide
 457097-27-7P, 3-Methoxy-N-[3-(4-methylpiperazin-1-yl)propyl]-4-(3-(pyrazin-2-yl)ureido)benzamide
 457097-29-9P, [2-[3-Methoxy-4-(3-(pyrazin-2-yl)ureido)benzoylamino]ethyl]trimethylammonium chloride
 457097-35-7P, N-Butyl-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide
 457097-36-8P, N-Benzyl-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide
 457097-37-9P, 4-Methoxy-N-phenethyl-3-(3-(pyrazin-2-yl)ureido)benzamide
 457097-38-0P, 4-Methoxy-N-(3-phenylpropyl)-3-(3-(pyrazin-2-yl)ureido)benzamide
 457097-39-1P, N-(2-(Benzenesulfonyl)ethyl)-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide
 457097-42-6P, N-(1H-Benzimidazol-2-ylmethyl)-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide
 457097-43-7P, N-[2-(1H-Indol-3-yl)ethyl]-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide
 457097-44-8P, 4-Methoxy-N-[3-(methylphenylamino)propyl]-3-(3-(pyrazin-2-yl)ureido)benzamide
 457097-46-0P, N-(2-Dimethylaminoethyl)-4-methoxy-N-methyl-3-(3-(pyrazin-2-yl)ureido)benzamide
 457097-47-1P, 4-Methoxy-N-(3-methylaminopropyl)-3-(3-(pyrazin-2-yl)ureido)benzamide

457097-48-2P, N-(3-Dimethylaminopropyl)-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-49-3P, N-(3-Dimethylaminopropyl)-4-methoxy-N-methyl-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-50-6P, 4-Methoxy-N-[3-(4-methylpiperazin-1-yl)propyl]-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-51-7P, [2-[4-Methoxy-3-(3-(pyrazin-2-yl)ureido)benzoylamino]ethyl]trimethylammonium chloride 457097-52-8P, 4-Methoxy-N-(3-(morpholin-4-yl)propyl)-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-59-5P, N-(1-Benzylpiperidin-4-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-61-9P, N-(3-Dimethylaminopropyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-63-1P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-(3-(morpholin-4-yl)propyl)benzamide 457097-65-3P, N-(2-(Dimethylamino)-2-phenylethyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-68-6P, N-(2-(Dimethylamino)-1-phenylethyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-70-0P, N-(1-Azabicyclo[2.2.2]oct-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-71-1P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3R)-1-(pyridin-2-yl)methylpyrrolidin-3-yl)benzamide 457097-74-4P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3R)-1-methylpyrrolidin-3-yl)benzamide 457097-77-7P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3R)-1-[(pyridin-4-yl)methyl]pyrrolidin-3-yl)benzamide 457097-79-9P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3S)-1-[(thiophen-2-yl)methyl]pyrrolidin-3-yl)benzamide 457097-81-3P, N-((3R)-1-Cyclohexylmethylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-84-6P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3S)-1-[(pyridin-2-yl)methyl]pyrrolidin-3-yl)benzamide 457097-86-8P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3S)-1-[(pyridin-3-yl)methyl]pyrrolidin-3-yl)benzamide 457097-87-9P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3S)-1-[(pyridin-4-yl)methyl]pyrrolidin-3-yl)benzamide 457097-90-4P, N-((3S)-1-Cyclohexylmethylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-97-1P, N-(1-Benzylpiperidin-4-ylmethyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457098-01-0P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzoic acid (3S)-1-benzylpyrrolidin-3-yl ester 457098-08-7P, 5-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-(2-(pyridin-2-yl)ethyl)-2-trifluoromethylbenzamide 457098-13-4P, 3-(3-Dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]benzoic acid 457098-17-8P, 4-[3-(5-Methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzoic acid 457098-21-4P, 3-(3-Dimethylaminopropoxy)-4-[3-(5-n-methylpyrazin-2-yl)ureido]benzamide 457098-22-5P, 3-(3-Dimethylaminopropoxy)-N,N-dimethyl-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457098-23-6P, N-Benzyl-3-(3-dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457098-24-7P, N-Benzyl-3-(3-dimethylaminopropoxy)-N-methyl-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457098-25-8P, 3-(3-Dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]-N-(2-(morpholin-4-yl)ethyl)benzamide 457098-26-9P, 3-(3-Dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]-N-[2-(1-methylpyrrolidin-2-yl)ethyl]benzamide 457098-27-0P, N-(2-Dimethylaminoethyl)-3-(3-dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457098-29-2P, 4-[3-(5-Methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide 457098-30-5P, N-Methyl-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide 457098-31-6P, N-Dimethyl-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide 457098-32-7P, N-Benzyl-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide 457098-33-8P, N-Benzyl-N-methyl-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-


ylmethoxy)benzamide 457098-34-9P, 4-[3-(5-Methylpyrazin-2-yl)ureido]-N-(2-(morpholin-4-yl)ethyl)-3-(pyridin-3-ylmethoxy)benzamide 457098-35-0P, 4-[3-(5-Methylpyrazin-2-yl)ureido]-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-3-(pyridin-3-ylmethoxy)benzamide 457098-36-1P, N-(2-Dimethylaminoethyl)-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide 457098-52-1P, 1-(5-Methylpyrazin-2-yl)-3-[2-(pyridin-3-ylmethoxy)-5-trifluoromethylphenyl]urea 457099-04-6P, 1-[5-Fluoro-2-(pyridin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-05-7P, 1-[5-Fluoro-2-(1-methylpiperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-06-8P, 1-[5-Fluoro-2-(1-methylpiperidin-4-yloxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-07-9P, 1-[4-Fluoro-2-(pyridin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-08-0P, 1-[4-Fluoro-2-(1-methylpiperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-09-1P, 1-[4-Fluoro-2-(1-methylpiperidin-4-yloxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-10-4P, 1-[3,4-Difluoro-2-(pyridin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-53-5P, 1-(2-Methoxy-4-methoxymethylphenyl)-3-(5-methylpyrazin-2-yl)urea 457099-54-6P, 1-(4-Benzoyloxymethyl-2-methoxyphenyl)-3-(5-methylpyrazin-2-yl)urea 457099-57-9P, 1-[4-[(Benzylamino)methyl]-2-methoxyphenyl]-3-(5-methylpyrazin-2-yl)urea 457099-60-4P, 1-(2-Methoxy-4-[(methylamino)methyl]phenyl)-3-(5-methylpyrazin-2-yl)urea 457099-65-9P, 1-(4-[(Dimethylamino)methyl]-2-methoxyphenyl)-3-(5-methylpyrazin-2-yl)urea 457099-68-2P, 1-[2-Methoxy-4-[(thiophen-2-ylmethyl)amino]methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-69-3P, 1-[2-Methoxy-4-[(thiophen-3-ylmethyl)amino]methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-70-6P, 1-[4-[(Furan-2-ylmethyl)amino]methyl]-2-methoxyphenyl]-3-(5-methylpyrazin-2-yl)urea 457099-71-7P, 1-[4-[(Furan-3-ylmethyl)amino]methyl]-2-methoxyphenyl]-3-(5-methylpyrazin-2-yl)urea 457099-72-8P, 1-[2-Methoxy-4-[(2-methoxybenzylamino)methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-73-9P, 1-[2-Methoxy-4-[(3-methoxybenzylamino)methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-74-0P, 1-[2-Methoxy-4-[(4-methoxybenzylamino)methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea 457099-75-1P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]acetamide 457099-76-2P, 2-Methoxy-N-[3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]acetamide 457099-77-3P, 2-(Dimethylamino)-N-[3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]acetamide 457099-78-4P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]-2-(pyridin-2-yl)acetamide 457099-79-5P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]-2-(4-methoxyphenyl)acetamide 457099-80-8P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]benzamide 457099-81-9P, Pyridine-2-carboxylic acid 3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzylamide 457099-82-0P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]nicotinamide 457099-83-1P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]isonicotinamide 457099-84-2P, Thiophene-2-carboxylic acid 3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzylamide 457099-85-3P, 3-(Dimethylamino)-N-[3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]benzamide 457099-86-4P 457099-87-5P 457099-88-6P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]benzenesulfonamide 457099-89-7P, N-[3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]-2-trifluoromethoxybenzenesulfonamide 457099-90-0P, 3-Methoxy-N-[3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzyl]benzenesulfonamide 457099-91-1P, 4-Methoxy-N-[3-methoxy-4-[3-(5-methylpyrazin-2-

yl)ureido]benzyl]benzenesulfonamide 457099-92-2P,
 Pyridine-2-sulfonic acid 3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzylamide 457099-93-3P, N-(2-Methoxy-3-((2-(4-morpholinyl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea 457099-94-4P, N-(2-Methoxy-3-((2-(1-methylpyrrolidin-2-yl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea 457099-95-5P, N-(4-((2-Chloroethyl)carbamoyl)-2-methoxyphenyl)-N'-(2-pyrazinyl)urea 457099-96-6P, N-(2-Methoxy-4-((2-(4-morpholinyl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea 457099-97-7P, N-(2-Methoxy-4-((2-(1-methylpyrrolidin-2-yl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea 457099-98-8P, N-(2-Methoxy-4-((2-((methylsulfonyl)amino)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea 457099-99-9P, N-(3-(Ethyl(methyl)carbamoyl)-2-methoxyphenyl)-N'-(2-pyrazinyl)urea 457100-00-4P, N-(2-Methoxy-5-methylphenyl)-N'-(4-pyrimidinyl)urea 458523-51-8P, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3R)-1-[(thiophen-2-yl)methyl]pyrrolidin-3-yl)benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryl and heteroaryl urea selective Chk1 inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)


RN 196868-94-7 HCAPLUS

CN Urea, N-(4-chloro-2-methoxyphenyl)-N'-pyrazinyl- (9CI) (CA INDEX NAME)




RN 457096-65-0 HCAPLUS

CN Urea, N-[2-(difluoromethoxy)phenyl]-N'-pyrazinyl- (9CI) (CA INDEX NAME)




RN 457096-67-2 HCAPLUS

CN Urea, N-[2-(methylthio)phenyl]-N'-pyrazinyl- (9CI) (CA INDEX NAME)



RN 457096-70-7 HCAPLUS


CN Butanoic acid, 4-[[4-methoxy-3-[(pyrazinylamino)carbonyl]amino]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 457096-72-9 HCAPLUS


CN 2-Pyrrolidinecarboxamide, N-[4-methoxy-3-[(pyrazinylamino)carbonyl]amino]phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457096-73-0 HCAPLUS

CN Methanesulfonamide, N-[4-methoxy-3-[(pyrazinylamino)carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 457096-77-4 HCAPLUS

CN Acetamide, 2-(dimethylamino)-N-[3-methoxy-4-[(pyrazinylamino)carbonyl]amino]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 457096-76-3


CMF C16 H20 N6 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 457096-82-1 HCAPLUS

CN Benzoic acid, 3-methoxy-4-[[pyrazinylamino]carbonyl]amino] - (9CI) (CA INDEX NAME)




RN 457096-85-4 HCAPLUS

CN Benzamide, N-butyl-3-methoxy-4-[[pyrazinylamino]carbonyl]amino] - (9CI) (CA INDEX NAME)




RN 457096-86-5 HCAPLUS

CN Urea, N-[2-methoxy-4-[[methyl(phenylmethyl)amino]methyl]phenyl]-N'-(5-methylpyrazinyl) - (9CI) (CA INDEX NAME)




RN 457096-87-6 HCAPLUS

CN Benzamide, 3-methoxy-N-(phenylmethyl)-4-[[pyrazinylamino]carbonyl]amino]-(9CI) (CA INDEX NAME)




RN 457096-89-8 HCAPLUS

CN Benzamide, 3-methoxy-N-(2-phenylethyl)-4-[[pyrazinylamino]carbonyl]amino]-(9CI) (CA INDEX NAME)




RN 457096-90-1 HCAPLUS

CN Benzamide, 3-methoxy-N-(3-phenylpropyl)-4-[[pyrazinylamino]carbonyl]amino]-(9CI) (CA INDEX NAME)




RN 457096-92-3 HCAPLUS


CN Benzamide, 3-methoxy-N-[2-(phenylsulfonyl)ethyl]-4-[[pyrazinylamino]carbonyl]amino]-(9CI) (CA INDEX NAME)




RN 457096-95-6 HCAPLUS
 CN Benzamide, N-[(4-iodophenyl)methyl]-3-methoxy-4-
 [[pyrazinylamino)carbonyl]amino] - (9CI) (CA INDEX NAME)




RN 457097-01-7 HCAPLUS
 CN Benzamide, N-(1H-benzimidazol-2-ylmethyl)-3-methoxy-4-
 [[pyrazinylamino)carbonyl]amino] - (9CI) (CA INDEX NAME)



RN 457097-04-0 HCAPLUS
 CN Benzamide, N-[2-(1H-indol-3-yl)ethyl]-3-methoxy-4-
 [[pyrazinylamino)carbonyl]amino] - (9CI) (CA INDEX NAME)




RN 457097-05-1 HCAPLUS
 CN Benzamide, 3-methoxy-N-[3-(methylphenylamino)propyl]-4-
 [[pyrazinylamino)carbonyl]amino] - (9CI) (CA INDEX NAME)




RN 457097-16-4 HCAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-3-methoxy-N-methyl-4-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-18-6 HCAPLUS

CN Benzamide, 3-methoxy-N-[3-(methylamino)propyl]-4-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-21-1 HCAPLUS

CN Benzamide, N-[3-(dimethylamino)propyl]-3-methoxy-4-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-23-3 HCAPLUS

CN Benzamide, N-[3-(dimethylamino)propyl]-3-methoxy-N-methyl-4-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-25-5 HCAPLUS

CN Benzamide, 3-methoxy-N-[3-(4-morpholinyl)propyl]-4-
[[pyrazinylamino]carbonyl]amino] - (9CI) (CA INDEX NAME)




RN 457097-27-7 HCAPLUS

CN Benzamide, 3-methoxy-N-[3-(4-methyl-1-piperazinyl)propyl]-4-
[[pyrazinylamino]carbonyl]amino] - (9CI) (CA INDEX NAME)



RN 457097-29-9 HCAPLUS


CN Ethanaminium, 2-[[3-methoxy-4-[[pyrazinylamino]carbonyl]amino]benzoyl]amino]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)



Cl⁻


RN 457097-35-7 HCAPLUS

CN Benzamide, N-butyl-4-methoxy-3-[[pyrazinylamino]carbonyl]amino] - (9CI)
(CA INDEX NAME)




RN 457097-36-8 HCAPLUS

CN Benzamide, 4-methoxy-N-(phenylmethyl)-3-[[pyrazinylamino]carbonyl]amino] - (9CI) (CA INDEX NAME)




RN 457097-37-9 HCAPLUS

CN Benzamide, 4-methoxy-N-(2-phenylethyl)-3-[[pyrazinylamino]carbonyl]amino] - (9CI) (CA INDEX NAME)




RN 457097-38-0 HCAPLUS

CN Benzamide, 4-methoxy-N-(3-phenylpropyl)-3-[[pyrazinylamino]carbonyl]amino] - (9CI) (CA INDEX NAME)




RN 457097-39-1 HCAPLUS

CN Benzamide, 4-methoxy-N-[2-(phenylsulfonyl)ethyl]-3-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-42-6 HCAPLUS

CN Benzamide, N-(1H-benzimidazol-2-ylmethyl)-4-methoxy-3-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-43-7 HCAPLUS

CN Benzamide, N-[2-(1H-indol-3-yl)ethyl]-4-methoxy-3-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-44-8 HCAPLUS

CN Benzamide, 4-methoxy-N-[3-(methylphenylamino)propyl]-3-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-46-0 HCAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-4-methoxy-N-methyl-3-
[[pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-47-1 HCAPLUS

CN Benzamide, 4-methoxy-N-[3-(methylamino)propyl]-3-
[[pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-48-2 HCAPLUS

CN Benzamide, N-[3-(dimethylamino)propyl]-4-methoxy-3-
[[pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-49-3 HCAPLUS

CN Benzamide, N-[3-(dimethylamino)propyl]-4-methoxy-N-methyl-3-[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-50-6 HCAPLUS

CN Benzamide, 4-methoxy-N-[3-(4-methyl-1-piperazinyl)propyl]-3-[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-51-7 HCAPLUS


CN Ethanaminium, 2-[[4-methoxy-3-[[pyrazinylamino]carbonyl]amino]benzoyl]amino]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)



● Cl⁻


RN 457097-52-8 HCAPLUS

CN Benzamide, 4-methoxy-N-[3-(4-morpholinyl)propyl]-3-
[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-59-5 HCAPLUS

CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 457097-61-9 HCAPLUS

CN Benzamide, N-[3-(dimethylamino)propyl]-3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-63-1 HCAPLUS

CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 457097-65-3 HCAPLUS

CN Benzamide, N-[2-(dimethylamino)-2-phenylethyl]-3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457097-68-6 HCAPLUS

CN Benzamide, N-[2-(dimethylamino)-1-phenylethyl]-3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-70-0 HCAPLUS


CN Benzamide, N-1-azabicyclo[2.2.2]oct-3-yl-3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-71-1 HCAPLUS

CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3R)-1-(2-pyridinylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457097-74-4 HCAPLUS

CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3R)-1-methyl-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457097-77-7 HCAPLUS

CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3R)-1-(4-pyridinylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 457097-79-9 HCAPLUS

CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3S)-

1-(2-thienylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457097-81-3 HCAPLUS

CN Benzamide, N-[(3R)-1-(cyclohexylmethyl)-3-pyrrolidinyl]-3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457097-84-6 HCAPLUS

CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3S)-1-(2-pyridinylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457097-86-8 HCAPLUS

CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3S)-1-(3-pyridinylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457097-87-9 HCAPLUS

CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(4S)-1-(4-pyridinylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457097-90-4 HCAPLUS


CN Benzamide, N-[(3S)-1-(cyclohexylmethyl)-3-pyrrolidinyl]-3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457097-97-1 HCAPLUS


CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 457098-01-0 HCAPLUS


CN Benzoic acid, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-, (3S)-1-(phenylmethyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 457098-08-7 HCAPLUS


CN Benzamide, 5-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[2-(2-pyridinyl)ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 457098-13-4 HCAPLUS
 CN Benzoic acid, 3-[3-(dimethylamino)propoxy]-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457098-17-8 HCAPLUS
 CN Benzoic acid, 4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 457098-21-4 HCAPLUS
 CN Benzamide, 3-[3-(dimethylamino)propoxy]-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457098-22-5 HCAPLUS
 CN Benzamide, 3-[3-(dimethylamino)propoxy]-N,N-dimethyl-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457098-23-6 HCAPLUS
 CN Benzamide, 3-[3-(dimethylamino)propoxy]-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 457098-24-7 HCAPLUS
 CN Benzamide, 3-[3-(dimethylamino)propoxy]-N-methyl-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 457098-25-8 HCAPLUS
 CN Benzamide, 3-[3-(dimethylamino)propoxy]-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 457098-26-9 HCAPLUS
 CN Benzamide, 3-[3-(dimethylamino)propoxy]-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-

(9CI) (CA INDEX NAME)




RN 457098-27-0 HCAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-3-[3-(dimethylamino)propoxy]-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457098-29-2 HCAPLUS

CN Benzamide, 4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 457098-30-5 HCAPLUS

CN Benzamide, N-methyl-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 457098-31-6 HCAPLUS

CN Benzamide, N,N-dimethyl-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 457098-32-7 HCAPLUS

CN Benzamide, 4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-(phenylmethyl)-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 457098-33-8 HCAPLUS

CN Benzamide, N-methyl-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-(phenylmethyl)-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 457098-34-9 HCAPLUS

CN Benzamide, 4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[2-(4-morpholinyl)ethyl]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 457098-35-0 HCAPLUS

CN Benzamide, 4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 457098-36-1 HCAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 457098-52-1 HCAPLUS


CN Urea, N-(5-methylpyrazinyl)-N'-[2-(3-pyridinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 457099-04-6 HCAPLUS
 CN Urea, N-[5-fluoro-2-(3-pyridinylmethoxy)phenyl]-N'-(5-methylpyrazinyl)-
 (9CI) (CA INDEX NAME)




RN 457099-05-7 HCAPLUS
 CN Urea, N-[5-fluoro-2-[(1-methyl-3-piperidinyl)methoxy]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)




RN 457099-06-8 HCAPLUS
 CN Urea, N-[5-fluoro-2-[(1-methyl-4-piperidinyl)oxy]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)




RN 457099-07-9 HCAPLUS
 CN Urea, N-[4-fluoro-2-(3-pyridinylmethoxy)phenyl]-N'-(5-methylpyrazinyl)-
 (9CI) (CA INDEX NAME)




RN 457099-08-0 HCAPLUS
 CN Urea, N-[4-fluoro-2-[(1-methyl-3-piperidinyl)methoxy]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)




RN 457099-09-1 HCAPLUS
 CN Urea, N-[4-fluoro-2-[(1-methyl-4-piperidinyl)oxy]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)




RN 457099-10-4 HCAPLUS
 CN Urea, N-[3,4-difluoro-2-(3-pyridinylmethoxy)phenyl]-N'-(5-methylpyrazinyl)-
 (9CI) (CA INDEX NAME)




RN 457099-53-5 HCAPLUS
CN Urea, N-[2-methoxy-4-(methoxymethyl)phenyl]-N'-(5-methylpyrazinyl)- (9CI)
(CA INDEX NAME)




RN 457099-54-6 HCAPLUS
CN Urea, N-[2-methoxy-4-[(phenylmethoxy)methyl]phenyl]-N'-(5-methylpyrazinyl)-
(9CI) (CA INDEX NAME)



RN 457099-57-9 HCAPLUS
CN Urea, N-[2-methoxy-4-[(phenylmethyl)amino]methyl]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)




RN 457099-60-4 HCAPLUS
CN Urea, N-[2-methoxy-4-[(methylamino)methyl]phenyl]-N'-(5-methylpyrazinyl)-
(9CI) (CA INDEX NAME)




RN 457099-65-9 HCAPLUS

CN Urea, N-[4-[(dimethylamino)methyl]-2-methoxyphenyl]-N'-(5-methylpyrazinyl)-
(9CI) (CA INDEX NAME)



RN 457099-68-2 HCAPLUS


CN Urea, N-[2-methoxy-4-[[2-(thienylmethyl)amino]methyl]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)




RN 457099-69-3 HCAPLUS

CN Urea, N-[2-methoxy-4-[[3-(thienylmethyl)amino]methyl]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 457099-70-6 HCAPLUS


CN Urea, N-[4-[[[2-(furan-2-ylmethyl)amino]methyl]-2-methoxyphenyl]-N'-(5-methylpyrazinyl)]- (9CI) (CA INDEX NAME)




RN 457099-71-7 HCAPLUS

CN Urea, N-[4-[[[3-(furan-2-ylmethyl)amino]methyl]-2-methoxyphenyl]-N'-(5-methylpyrazinyl)]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 457099-72-8 HCAPLUS
 CN Urea, N-[2-methoxy-4-[[[(2-methoxyphenyl)methyl]amino]methyl]phenyl]-N'-(5-methylpyrazinyl)-(9CI) (CA INDEX NAME)




RN 457099-73-9 HCAPLUS
 CN Urea, N-[2-methoxy-4-[[[(3-methoxyphenyl)methyl]amino]methyl]phenyl]-N'-(5-methylpyrazinyl)-(9CI) (CA INDEX NAME)




RN 457099-74-0 HCAPLUS

CN Urea, N-[2-methoxy-4-[[[(4-methoxyphenyl)methyl]amino]methyl]phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)




RN 457099-75-1 HCAPLUS

CN Acetamide, N-[[3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 457099-76-2 HCAPLUS

CN Acetamide, 2-methoxy-N-[[3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 457099-77-3 HCAPLUS

CN Acetamide, 2-(dimethylamino)-N-[[3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 457099-78-4 HCAPLUS

CN 2-Pyridineacetamide, N-[[[3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 457099-79-5 HCAPLUS

CN Benzeneacetamide, 4-methoxy-N-[[[3-methoxy-4-[[[5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 457099-80-8 HCAPLUS

CN Benzamide, N-[[3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 457099-81-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-[[[3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 457099-82-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 457099-83-1 HCAPLUS

CN 4-Pyridinecarboxamide, N-[[3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 457099-84-2 HCAPLUS

CN 2-Thiophenecarboxamide, N-[[3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 457099-85-3 HCAPLUS


CN Benzamide, 3-(dimethylamino)-N-[[3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 457099-86-4 HCAPLUS

CN 1H-Pyrazole-4-carboxamide, N-[[[3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]-1-phenyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 457099-87-5 HCAPLUS


CN 2-Thiophenesulfonamide, N-[[[3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX

NAME)




RN 457099-88-6 HCAPLUS

CN Benzenesulfonamide, N-[[3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 457099-89-7 HCAPLUS

CN Benzenesulfonamide, N-[[3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]-2-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 457099-90-0 HCAPLUS

CN Benzenesulfonamide, 3-methoxy-N-[[3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 457099-91-1 HCAPLUS

CN Benzenesulfonamide, 4-methoxy-N-[[3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 457099-92-2 HCAPLUS

CN 2-Pyridinesulfonamide, N-[[3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 457099-93-3 HCAPLUS

CN Benzamide, 2-methoxy-N-[2-(4-morpholinyl)ethyl]-3-[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457099-94-4 HCAPLUS

CN Benzamide, 2-methoxy-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-3-[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457099-95-5 HCAPLUS

CN Benzamide, N-(2-chloroethyl)-3-methoxy-4-[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457099-96-6 HCAPLUS

CN Benzamide, 3-methoxy-N-[2-(4-morpholinyl)ethyl]-4-
[[pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457099-97-7 HCAPLUS

CN Benzamide, 3-methoxy-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-
[[pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457099-98-8 HCAPLUS

CN Benzamide, 3-methoxy-N-[2-[(methylsulfonyl)amino]ethyl]-4-
[[pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 457099-99-9 HCAPLUS

CN Benzamide, N-ethyl-2-methoxy-N-methyl-3-[[pyrazinylamino)carbonyl]amino]-
(9CI) (CA INDEX NAME)




RN 457100-00-4 HCAPLUS
CN Urea, N-(2-methoxy-5-methylphenyl)-N'-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 458523-51-8 HCAPLUS
CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3R)-1-(2-thienylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:762759 HCAPLUS
DOCUMENT NUMBER: 135:298777
TITLE: Preparation of aminosulfonylpyridine phenylurea derivatives as interleukine-8 receptor antagonists
INVENTOR(S): Palovich, Michael R.; Widdowson, Katherine L.; Nie, Hong
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001076530	A2	20011018	WO 2001-US11102	20010405
WO 2001076530	A3	20020228		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001053172	A5	20011023	AU 2001-53172	20010405
PRIORITY APPLN. INFO.:			US 2000-196022P	P 20000407
			WO 2001-US11102	W 20010405

OTHER SOURCE(S): MARPAT 135:298777

AB This invention relates to novel compds. and compns. thereof useful in the treatment of disease states mediated by the chemokine, interleukin-8 (IL-8). To a soln. of 4-(aminosulfonyl)-3-chloro-3-5-hydroxy-6-aminopyridine (3.9 mmol) and 2-bromophenylisocyanate (4.6 mmol) in 5 mL of N,N-dimethylformamide was stirred at room temp. for 20 h. The mixt. was dild. with Et acetate and washed with water to give the crude material which was purified to obtain N-(6-(4-aminosulfonyl)-3-chloro-5-hydroxypyridine)-N'-(2-bromophenyl)urea (I). The IC50 of I in hamster ovary cells IL-8 receptors was <30 .mu.M.

IC ICM A61K

CC 1-7 (Pharmacology)

Section cross-reference(s): 27


IT **Neoplasm**
 (central nervous system; prepn. of aminosulfonylpyridine phenylurea derivs. as interleukine-8 receptor antagonists)

IT 367264-36-6P 367264-44-6P 367264-45-7P 367264-47-9P
 367264-49-1P 367264-51-5P 367264-53-7P 367264-55-9P
 367264-57-1P 367264-59-3P 367264-61-7P 367264-62-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. of aminosulfonylpyridine phenylurea derivs. as interleukine-8 receptor antagonists)

IT 367264-49-1P 367264-51-5P 367264-61-7P
 367264-62-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. of aminosulfonylpyridine phenylurea derivs. as interleukine-8 receptor antagonists)


RN 367264-49-1 HCAPLUS

CN 4-Pyridazinesulfonamide, 6-[[[(2-bromophenyl)amino]carbonyl]amino]-3-chloro-5-hydroxy- (9CI) (CA INDEX NAME)




RN 367264-51-5 HCAPLUS

CN 4-Pyridazinesulfonamide, 3-chloro-6-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-5-hydroxy- (9CI) (CA INDEX NAME)




RN 367264-61-7 HCAPLUS

CN 4-Pyridazinesulfonamide, 6-[[[(2-bromophenyl)amino]carbonyl]amino]-3-cyano-5-hydroxy- (9CI) (CA INDEX NAME)



RN 367264-62-8 HCAPLUS

CN 4-Pyridazinesulfonamide, 3-cyano-6-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-5-hydroxy- (9CI) (CA INDEX NAME)



L18 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:545724 HCAPLUS

DOCUMENT NUMBER: 135:147398

TITLE: Peptidomimetic modulators of cell adhesion

INVENTOR(S): Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie Denise; Wang, Shoameng; Hu, Zengjian

PATENT ASSIGNEE(S): Adherex Technologies, Inc., Can.

SOURCE: PCT Int. Appl., 416 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053331	A2	20010726	WO 2001-US2508	20010124
WO 2001053331	A3	20020711		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2000-491078 A 20000124

OTHER SOURCE(S): MARPAT 135:147398

AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

IC ICM C07K007-00

CC 1-3 (Pharmacology)

Section cross-reference(s): 34, 63

IT **Neoplasm**

Skin

(drug delivery to; peptidomimetic modulators of cell adhesion)

IT Ovary, **neoplasm**

(inhibitors; peptidomimetic modulators of cell adhesion)

IT Bladder

(neoplasm, inhibitors; peptidomimetic modulators of cell adhesion)

IT Bladder

(neoplasm; peptidomimetic modulators of cell adhesion)

IT Antitumor agents

Bioreactors

Bond angle

Cell migration

Combinatorial library

Drug delivery systems

Drug screening

Drug targeting

Electrostatic charge

Epithelium

Hydrophobicity

Melanoma

Membrane, biological

Microparticles

Molecular modeling

Multiple sclerosis

Oligodendrocyte

Ovary, neoplasm

Peptidomimetics

Protein sequences

QSAR (structure-activity relationship)

Schwann cell

Steric effects

Transplant and Transplantation

Transplant and Transplantation

Ultrathin films

Wound healing

Wound healing promoters

(peptidomimetic modulators of cell adhesion)

IT 351857-73-3 351857-74-4 351857-75-5 351857-76-6 351857-77-7

351857-78-8 351857-79-9 351857-80-2 351857-81-3D, derivs.

351857-82-4 351857-83-5 351857-84-6 351857-85-7

351857-86-8 351857-87-9 351857-88-0D, glycoside deriv. 351857-89-1

351857-90-4 351857-91-5 351857-92-6 351857-93-7 351857-94-8

351857-95-9 351857-96-0 351857-97-1 351857-98-2 351857-99-3

351858-00-9D, glucuronic acid derivs. 351858-01-0 351858-02-1

351858-03-2 351858-04-3 351858-05-4 351858-08-7 351858-09-8

351858-10-1 351858-11-2 351858-12-3 351858-13-4 351858-14-5

351858-15-6 351858-16-7 351858-17-8 351858-18-9 351858-19-0

351858-20-3 351858-21-4 351858-22-5 351858-23-6 351858-24-7

351858-25-8 351858-26-9 351858-27-0 351858-28-1 351858-29-2

351858-30-5 351858-31-6 351858-32-7 351858-33-8 351858-34-9

351858-35-0 351858-36-1 351858-37-2 351858-38-3 351858-39-4

351858-40-7 351858-41-8 351858-42-9 351858-43-0 351858-44-1

351858-45-2 351858-47-4 351858-48-5 351858-49-6 351858-50-9

351858-51-0 351858-52-1 351858-53-2 351858-54-3 351858-55-4

351858-56-5 351858-57-6 351858-58-7 351858-59-8 351858-60-1

351858-61-2 351858-62-3 351858-63-4 351858-64-5 351858-65-6

351858-66-7 351858-67-8 351858-68-9 351858-69-0 351858-70-3

351858-71-4 351858-72-5 351858-73-6 351858-74-7 351858-76-9

351858-81-6 351858-82-7 351858-84-9 351858-87-2 351858-92-9

351858-93-0 351859-05-7 351859-08-0 351859-09-1 351859-10-4

351859-11-5 351859-12-6 351859-13-7 351859-14-8 351859-15-9

351859-16-0 351859-17-1 351859-18-2 351859-19-3 351859-20-6

351859-21-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(peptidomimetic modulators of cell adhesion)


IT 351857-85-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(peptidomimetic modulators of cell adhesion)

RN 351857-85-7 HCAPLUS

CN Urea, N-(2-amino-6-chloro-4-pyrimidinyl)-N'-phenyl- (9CI) (CA INDEX NAME)



L18 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:425740 HCAPLUS

DOCUMENT NUMBER: 131:73648

TITLE: Inhibition of raf kinase using substituted heterocyclic ureas

INVENTOR(S): Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: PCT Int. Appl., 163 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932106	A1	19990701	WO 1998-US26078	19981222
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2315717	AA	19990701	CA 1998-2315717	19981222
AU 9921989	A1	19990712	AU 1999-21989	19981222
EP 1047418	A1	20001102	EP 1998-965981	19981222
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2001526220	T2	20011218	JP 2000-525097	19981222
BR 9814374	A	20020514	BR 1998-14374	19981222
NO 2000003232	A	20000821	NO 2000-3232	20000621
PRIORITY APPLN. INFO.:			US 1997-996343	A 19971222

OTHER SOURCE(S): MARPAT 131:73648

GI



- AB A method for treatment of cancerous cell growth mediated by raf kinase comprises administration of urea derivs. ANHCONHB [I; A = substituted isoxazolyl, thienyl, thiadiazolyl, furyl, pyrazolyl, etc.; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl contg. 5-6 membered arom. structure contg. 0-4 N, O, or S atoms]. Reaction of 4-phenyloxyphenyl isocyanate with 5-amino-3-tert-butylisoxazole in methylene chloride and heating at reflux temp. for 2 days gave title compd. II. In an in vitro raf kinase assay, I displayed IC₅₀ values of 1-10 μ M.
- IC ICM A61K031-34
ICS A61K031-38; A61K031-41; A61K031-415; A61K031-42; A61K031-425; A61K031-44; A61K031-47; C07D215-20; C07D231-40; C07D261-14; C07D257-06; C07D263-48; C07D271-113; C07D277-28; C07D285-135; C07D307-66; C07D333-36; C07D401-10; C07D401-12
- CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 7
- IT Phosphoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(gene c-raf; prepn. of substituted heterocyclic ureas for treatment of **cancerous** cell growth mediated by raf kinase)
- IT Antitumor agents
(prepn. of substituted heterocyclic ureas for treatment of **cancerous** cell growth mediated by raf kinase)
- IT 229003-12-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; prepn. of substituted heterocyclic ureas for treatment of **cancerous** cell growth mediated by raf kinase)
- IT 3619-17-8P 4302-24-3P, 3-Chloro-4,4-dimethylpent-2-enal 6337-24-2P
13472-85-0P 18994-90-6P 27692-74-6P 28232-34-0P 28232-52-2P
29212-25-7P, 5-tert-Butyl-2-thiophenecarboxylic acid 31465-36-8P
32361-76-5P 36089-89-1P 38895-88-4P 51834-97-0P 55809-53-5P,
5-tert-Butyl-3-isoxazolyl isocyanate 62248-47-9P 62248-51-5P
63806-67-7P, 5-Methyl-2-(azidocarbonyl)thiophene 64064-63-7P
65283-97-8P 70991-08-1P 75782-77-3P 88786-11-2P 92575-23-0P
116289-71-5P 135680-03-4P 178809-75-1P 216574-46-8P 216574-47-9P
216574-72-0P 220000-87-3P 228401-26-1P 228401-27-2P 228401-28-3P
228401-29-4P 228401-31-8P 228401-32-9P 228401-33-0P 228401-36-3P
228401-37-4P 228401-38-5P 228401-39-6P 228401-40-9P 228401-41-0P
228401-43-2P 228401-44-3P 229003-11-6P 229003-13-8P 229003-14-9P
229003-15-0P 229003-16-1P 229003-17-2P 229003-18-3P 229003-19-4P,
Methyl 5-tert-butyl-2-thiophenecarboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of substituted heterocyclic ureas for treatment of **cancerous** cell growth mediated by raf kinase)

IT 228998-95-6P 228999-08-4P 228999-28-8P 228999-64-2P 229002-05-5P
229002-65-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of substituted heterocyclic ureas for treatment of **cancerous** cell growth mediated by raf kinase)

IT 227623-30-5P 228998-90-1P 228998-91-2P 228998-92-3P 228998-93-4P
228998-94-5P 228998-96-7P 228998-97-8P 228998-98-9P 228998-99-0P
228999-00-6P 228999-01-7P 228999-02-8P 228999-03-9P 228999-04-0P
228999-05-1P 228999-06-2P 228999-07-3P 228999-09-5P 228999-10-8P
228999-11-9P 228999-12-0P 228999-13-1P 228999-14-2P 228999-15-3P
228999-16-4P 228999-17-5P 228999-18-6P 228999-19-7P 228999-20-0P
228999-21-1P 228999-22-2P 228999-23-3P 228999-24-4P 228999-25-5P
228999-26-6P 228999-27-7P 228999-29-9P 228999-30-2P 228999-31-3P
228999-32-4P 228999-33-5P 228999-34-6P 228999-35-7P 228999-36-8P
228999-37-9P 228999-38-0P 228999-39-1P 228999-40-4P 228999-41-5P
228999-42-6P 228999-43-7P 228999-44-8P 228999-45-9P 228999-46-0P
228999-47-1P 228999-48-2P 228999-49-3P 228999-50-6P 228999-51-7P
228999-52-8P 228999-53-9P 228999-54-0P 228999-55-1P 228999-56-2P
228999-57-3P 228999-58-4P 228999-59-5P 228999-60-8P 228999-61-9P
228999-62-0P 228999-63-1P 228999-65-3P 228999-66-4P 228999-67-5P
228999-68-6P 228999-69-7P 228999-70-0P 228999-71-1P 228999-72-2P
228999-73-3P 228999-74-4P 228999-75-5P 228999-76-6P 228999-77-7P
228999-78-8P 228999-79-9P 228999-80-2P 228999-81-3P 228999-82-4P
228999-83-5P 228999-84-6P 228999-85-7P 228999-86-8P 228999-87-9P
228999-88-0P 228999-89-1P 228999-90-4P 228999-91-5P 228999-92-6P
228999-93-7P 228999-94-8P 228999-95-9P 228999-96-0P 228999-97-1P
228999-98-2P 228999-99-3P 229000-00-4P 229000-01-5P 229000-02-6P
229000-03-7P 229000-04-8P 229000-05-9P 229000-06-0P 229000-07-1P
229000-08-2P 229000-09-3P 229000-10-6P 229000-11-7P 229000-12-8P
229000-13-9P 229000-14-0P 229000-15-1P 229000-16-2P 229000-17-3P
229000-18-4P 229000-19-5P 229000-20-8P 229000-21-9P 229000-22-0P
229000-23-1P 229000-24-2P 229000-25-3P 229000-26-4P 229000-27-5P
229000-28-6P 229000-29-7P 229000-30-0P 229000-31-1P 229000-32-2P
229000-33-3P 229000-34-4P 229000-35-5P 229000-36-6P 229000-37-7P
229000-38-8P 229000-39-9P 229000-40-2P 229000-41-3P 229000-42-4P
229000-43-5P 229000-44-6P 229000-45-7P 229000-46-8P 229000-47-9P
229000-48-0P 229000-49-1P 229000-50-4P 229000-51-5P 229000-52-6P
229000-53-7P 229000-54-8P 229000-55-9P 229000-56-0P 229000-57-1P
229000-58-2P 229000-59-3P 229000-60-6P 229000-61-7P 229000-62-8P
229000-63-9P 229000-64-0P 229000-65-1P 229000-66-2P 229000-67-3P
229000-68-4P 229000-69-5P 229000-71-9P 229000-72-0P 229000-73-1P
229000-74-2P 229000-75-3P 229000-76-4P 229000-77-5P 229000-78-6P
229000-79-7P 229000-80-0P 229000-81-1P 229000-82-2P 229000-83-3P
229000-84-4P 229000-85-5P 229000-86-6P 229000-87-7P 229000-88-8P
229000-89-9P 229000-90-2P 229000-91-3P 229000-92-4P 229000-93-5P
229000-94-6P 229000-95-7P 229000-96-8P 229000-97-9P 229000-98-0P
229000-99-1P 229001-00-7P 229001-01-8P 229001-03-0P 229001-05-2P
229001-07-4P 229001-08-5P 229001-09-6P 229001-10-9P 229001-11-0P
229001-12-1P 229001-14-3P 229001-16-5P 229001-17-6P 229001-18-7P
229001-19-8P 229001-20-1P 229001-21-2P 229001-22-3P 229001-23-4P
229001-24-5P 229001-25-6P 229001-26-7P 229001-27-8P 229001-28-9P
229001-29-0P 229001-30-3P 229001-31-4P 229001-32-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted heterocyclic ureas for treatment of
cancerous cell growth mediated by raf kinase)

IT 229001-33-6P 229001-34-7P 229001-35-8P 229001-36-9P
 229001-37-0P 229001-38-1P 229001-39-2P 229001-40-5P 229001-41-6P
 229001-42-7P 229001-43-8P 229001-44-9P 229001-45-0P 229001-46-1P
 229001-47-2P 229001-48-3P 229001-49-4P 229001-50-7P 229001-51-8P
 229001-52-9P 229001-53-0P 229001-54-1P 229001-55-2P 229001-56-3P
 229001-57-4P 229001-58-5P 229001-59-6P 229001-60-9P 229001-61-0P
 229001-62-1P 229001-63-2P 229001-64-3P 229001-65-4P 229001-66-5P
 229001-67-6P 229001-68-7P 229001-69-8P 229001-70-1P 229001-71-2P
 229001-72-3P 229001-73-4P 229001-74-5P 229001-75-6P 229001-76-7P
 229001-77-8P 229001-78-9P 229001-79-0P 229001-80-3P 229001-81-4P
 229001-82-5P 229001-83-6P 229001-84-7P 229001-85-8P 229001-86-9P
 229001-87-0P 229001-89-2P 229001-90-5P 229001-91-6P 229001-92-7P
 229001-93-8P 229001-94-9P 229001-95-0P 229001-96-1P 229001-97-2P
 229001-98-3P 229001-99-4P 229002-00-0P 229002-01-1P 229002-02-2P
 229002-03-3P 229002-04-4P 229002-06-6P 229002-07-7P 229002-08-8P
 229002-09-9P 229002-10-2P 229002-11-3P 229002-12-4P 229002-13-5P
 229002-14-6P 229002-15-7P 229002-16-8P 229002-17-9P 229002-18-0P
 229002-19-1P 229002-20-4P 229002-21-5P 229002-22-6P 229002-23-7P
 229002-24-8P 229002-25-9P 229002-26-0P 229002-27-1P 229002-28-2P
 229002-29-3P 229002-30-6P 229002-31-7P 229002-32-8P 229002-33-9P
 229002-34-0P 229002-35-1P 229002-36-2P 229002-37-3P 229002-38-4P
 229002-39-5P 229002-40-8P 229002-41-9P 229002-42-0P 229002-43-1P
 229002-44-2P 229002-45-3P 229002-46-4P 229002-47-5P 229002-48-6P
 229002-49-7P 229002-50-0P 229002-51-1P 229002-52-2P 229002-53-3P
 229002-55-5P 229002-56-6P 229002-57-7P 229002-59-9P 229002-60-2P
 229002-61-3P 229002-62-4P 229002-63-5P 229002-66-8P 229002-67-9P
 229002-70-4P 229002-72-6P 229002-74-8P 229002-75-9P 229002-76-0P
 229002-77-1P 229002-78-2P 229002-79-3P 229002-80-6P 229002-81-7P
 229002-82-8P 229002-83-9P 229002-84-0P 229002-85-1P 229002-86-2P
 229002-87-3P 229002-88-4P 229002-89-5P 229002-90-8P 229002-92-0P
 229002-93-1P 229002-94-2P 229002-95-3P 229002-96-4P 229002-97-5P
 229002-98-6P 229002-99-7P 229003-00-3P 229003-01-4P 229003-02-5P
 229003-03-6P 229003-04-7P 229003-05-8P 229003-06-9P 229003-07-0P
 229003-08-1P 229003-09-2P 229003-10-5P 229003-26-3P 229030-09-5P
 229176-71-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted heterocyclic ureas for treatment of
cancerous cell growth mediated by raf kinase)

IT 144378-33-6, Raf kinase

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)

(prepn. of substituted heterocyclic ureas for treatment of
cancerous cell growth mediated by raf kinase)

IT 75-26-3, 2-Bromopropane 75-97-8, Pinacolone 88-09-5, 2-Ethylbutyric acid 100-11-8, 4-Nitrobenzyl bromide 100-15-2, N-Methyl-4-nitroaniline 101-77-9 102-36-3, 3,4-Dichlorophenyl isocyanate 106-44-5, reactions 109-00-2, 3-Hydroxypyridine 123-30-8, 4-Aminophenol 150-76-5, 4-Methoxyphenol 153-78-6, 2-Aminofluorene 288-32-4, Imidazole, reactions 350-46-9, 1-Fluoro-4-nitrobenzene 353-07-1 400-74-8, 2-Fluoro-5-nitrobenzotrifluoride 542-69-8, 1-Iodobutane 547-63-7, Methyl isobutyrate 585-79-5, 1-Bromo-3-nitrobenzene 620-95-1, 3-Benzylpyridine 624-28-2, 2,5-Dibromopyridine 626-61-9, 4-Chloropyridine 673-09-6, 4-(4-Pyridinylthio)aniline 872-31-1, 3-Bromothiophene 1083-48-3, 4-(4-Nitrobenzyl)pyridine 1121-78-4, 5-Hydroxy-2-methylpyridine 1849-36-1 1918-79-2, 5-Methyl-2-thiophenecarboxylic acid 2033-89-8, 3,4-Dimethoxyphenol 2103-88-0,

2-Mercapto-4-phenylthiazole 3678-63-5 4418-61-5, 5-Aminotetrazole
 4548-45-2, 2-Chloro-5-nitropyridine 4556-23-4, 4-Mercaptopyridine
 4595-59-9, 5-Bromopyrimidine 5469-26-1, 1-Bromo-3,3-dimethyl-2-butanone
 7379-35-3, 4-Chloropyridine hydrochloride 21101-60-0,
 4-(4-Nitrophenylthio)phenol 22948-02-3, 3-Aminothiophenol 29264-35-5,
 4-(3-Carboxy-4-hydroxyphenoxy)-1-nitrobenzene 29509-06-6,
 3-Oxo-4-methylpentanenitrile 36265-31-3, 4-(4-Methylthiophenoxy)-1-
 nitrobenzene 41195-90-8, 2,3-Dichlorophenyl isocyanate 42732-49-0,
 3-Hydroxy-5-methylpyridine 55809-36-4, 3-Amino-5-tert-butylisoxazole
 59377-19-4, 4-Phenoxyphenyl isocyanate 59669-59-9, 5-Amino-3-tert-
 butylisoxazole 59669-71-5, 3-tert-Butyl-5-isoxazolyl isocyanate
 59997-51-2, 4,4-Dimethyl-3-oxopentanenitrile 73322-01-7,
 4-(2-Pyridinylthio)-1-nitrobenzene 76536-99-7, 5-Methyl-2-thiophene
 isocyanate 82560-12-1, 5-Amino-3-tert-butylpyrazole 91512-42-4,
 3-(2-Benzothiazolyloxy)aniline 102877-78-1, 4-(4-Pyridinyloxy)aniline
 118430-73-2, 5-Amino-3-tert-butyl-1-methylpyrazole 120771-21-3,
 5-Amino-4-methyl-3-tert-butylisoxazole 160040-74-4, 4-(4-
 Methylphenoxy)phenyl isocyanate 175137-03-8 229003-21-8 229003-22-9
 229003-23-0 229003-24-1 229003-25-2

RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; prepn. of substituted heterocyclic ureas for treatment of
cancerous cell growth mediated by raf kinase)


IT 229001-33-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of substituted heterocyclic ureas for treatment of
cancerous cell growth mediated by raf kinase)

RN 229001-33-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-5-isoxazolyl]-N'-[6-[4-(methylthio)phenoxy]-
 3-pyridazinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



|
SMe

REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT